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List of Abbreviations 
BMD, bone mineral density  
BMI, body mass index 
CI, confidence interval 
CKD, chronic kidney disease 
CVD, cardiovascular disease 
eGFR, estimated glomerular filtration rate 
HR, hazard ratio 
JAM-A, junctional adhesion molecule A  
NAFLD, nonalcoholic fatty liver disease 
NASH, nonalcoholic steatohepatitis 
NF-κB, nuclear factor–kappa B  
NFS, NAFLD fibrosis score  
OR, odds ratio 
PNPLA3, patatin-like phospholipase domain-containing 3  
RANKL, receptor activator of nuclear factor–kappa B 
T2DM, type 2 diabetes mellitus 
TM6SF2, trans-membrane 6 superfamily member 2  
TMA, trimethylamine  
TMAO, trimethylamine-N-oxide 
TNF, tumour necrosis factor 
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 3
1. ABSTRACT  
Key physiological functions of the liver, including glucose and lipid metabolism, become disturbed in 
the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated with a systemic 
inflammatory ‘milieu’ initiated in part by liver-secreted cytokines and molecules. Consequently, the 
pathophysiological effects of NAFLD extend beyond the liver with a large body of clinical evidence 
demonstrating NAFLD to be independently associated with both prevalent and incident cardiovascular 
disease (CVD), chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). The magnitude of 
risk of developing these extra-hepatic diseases parallels the underlying severity of NAFLD, such that 
patients with non-alcoholic steatohepatitis (NASH) appear to be at greater risk of incident CVD, CKD 
and T2DM than those with simple steatosis. Other modifiers of risk may include genetic variants [e.g., 
patatin-like phospholipase domain-containing 3 (PNPLA3) and trans-membrane 6 superfamily member 
2 (TM6SF2) polymorphisms], visceral adipose tissue accumulation, dietary intake and the gut 
microbiome. Emerging data also suggest that NAFLD may be a risk factor for colonic neoplasia and 
reduced bone mineral density, especially among men. Importantly, improvement/resolution of NAFLD 
is associated with a reduced incidence of T2DM and improved kidney function, adding weight to 
causality and suggesting liver focused treatments may reduce risk of extra-hepatic complications. 
Awareness of these associations is important for the clinicians such that CVD risk factor management, 
screening for T2DM and CKD are part of the routine management of patients with NAFLD.   
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2. INTRODUCTION  
Non-alcoholic fatty liver disease (NAFLD) is a very common pathologic condition worldwide that is 
closely associated with the clinical features of metabolic syndrome and is characterised by substantial 
inter-patient variability in severity and rate of liver disease progression.[1, 2]  
 
A purely liver-centric view is that NAFLD represents a spectrum of progressive liver disease occurring in 
the absence of excessive alcohol consumption that ranges from isolated intrahepatic triglyceride 
accumulation (simple steatosis); through intrahepatic triglyceride accumulation plus inflammation and 
hepatocyte injury (nonalcoholic steatohepatitis, NASH); and ultimately progresses to fibrosis/cirrhosis 
and potentially hepatocellular carcinoma.[3] Although a significant proportion of the population have 
NAFLD, only a minority progress to advanced liver disease or liver-related death.[3]  
 
However, this liver-centric view does not encompass the wider ramifications of NAFLD. Indeed, NAFLD 
is just one facet of a multisystem disease (Fig. 1) that confers substantially increased morbidity and 
mortality on those patients who are affected and where the most common causes of death are 
cardiovascular disease (CVD), followed by extra-hepatic malignancies and liver-related 
complications.[4, 5]  
 
This review mainly focuses on the principle extra-hepatic chronic diseases associated with NAFLD 
where there is now strongest evidence for a potential causal link: CVD, T2DM, chronic kidney disease 
[1, 2] and, to a lesser extent, certain types of extra-hepatic tumours and osteoporosis.  
 
 
3. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF CARDIOVASCULAR DISEASE  
That NAFLD is associated with an increased risk of CVD is unsurprising, given the close associations 
between NAFLD and the established CVD risk factors encapsulated by the metabolic syndrome, 
including abdominal obesity, hypertension, atherogenic dyslipidaemia and insulin 
resistance/dysglycaemia.[6, 7, 8] Highlighting the intimacy of these associations is the observation 
that the increases in hepatic lipid accumulation are directly proportional to the severity of each 
component of the metabolic syndrome.[9] However, the nature and extent of these associations, 
whether simply due to a shared underlying aetiology or because the presence of NAFLD confers an 
additional risk, remains the subject of much scrutiny. This attention is undoubtedly warranted as it 
has important clinical implications for screening and surveillance strategies in the growing number of 
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 5
patients with NAFLD. Addressing CVD risk in patients with NAFLD is also the aspect of the disease 
most amenable to medical management and so improving long-term clinical outcomes.  
 
Beyond the associations with traditional CVD risk factors, patients with NAFLD also exhibit a range of 
non-traditional CVD risk factors, including hyperuricaemia,[10, 11, 12] hypoadiponectinaemia [13, 14, 
15] and hypovitaminosis D.[16] The association with CKD, discussed later in this review, also confers 
an increased risk of CVD.[17] Other potentially contributing risk factors include increased levels of 
circulating proinflammatory markers (e.g., C-reactive protein, interleukin-6, tumour necrosis factor-
alpha and other hepatic acute-phase proteins), procoagulant factors (e.g., fibrinogen and 
plasminogen activator inhibitor-1) and adhesion molecules (e.g., vascular adhesion protein-1) that 
are likely to have been synthesised within the liver, especially in the presence of NASH.[18, 19, 20, 
21, 22, 23] 
 
Substantial epidemiological evidence links NAFLD with objectively assessed subclinical 
atherosclerosis and with an increased prevalence of clinically manifest CVD. In case-control studies, 
NAFLD has been linked with increased carotid artery intima-media thickness,[24, 25, 26, 27, 28] 
increased arterial wall stiffness,[29, 30] and impaired endothelium-dependent flow-mediated 
vasodilatation.[31, 32] Similarly, a meta-analysis of seven cross-sectional studies totalling 3497 
individuals concluded that ultrasound-diagnosed NAFLD was strongly associated with greater carotid-
artery intimal medial thickness and an increased prevalence of carotid atherosclerotic plaques.[33] 
These findings have since been supported by a larger meta-analysis that incorporated 27 studies and 
confirmed the association of NAFLD with various markers of subclinical atherosclerosis (including also 
increased coronary-artery calcium score) independent of traditional CVD risk factors and metabolic 
syndrome features.[34] Individuals with NAFLD amongst an occupational cohort of over 10000 South 
Korean people had an increased coronary-artery calcium score, independent of multiple CVD risk 
factors, including insulin resistance.[35] Case-control studies have also reported strong associations 
of NAFLD with early changes in left ventricular morphology and/or diastolic dysfunction,[36, 37, 38, 
39] impaired myocardial energy metabolism,[40, 41] and reduced coronary artery flow.[42]. Cohort 
studies in patients with biopsy-confirmed NAFLD/NASH also clearly demonstrated that CVD is the 
most common cause of death.[4, 5] 
 
Population-based cohort studies, such as the National Health and Nutrition Examination Survey 
(NHANES-III), also provide evidence of increased CVD prevalence in NAFLD. In approximately 11500 
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adult NHANES participants, NAFLD (diagnosed by ultrasonography) remained significantly associated 
with an increased prevalence of CVD after adjusting for major demographic, clinical and metabolic 
confounders.[43, 44] An Italian study in nearly 3000 outpatients with T2DM also demonstrated that 
those with ultrasound-diagnosed NAFLD had a higher prevalence of coronary, cerebrovascular and 
peripheral vascular disease, independent of traditional CVD risk factors, diabetes-related variables 
and other potential confounders.[45] Amongst patients undergoing clinically indicated coronary 
angiography, the presence of NAFLD also independently correlated with the severity of coronary 
artery disease.[46, 47, 48] Recently, a systematic review and meta-analysis incorporating almost 
165000 participants in 34 studies (21 cross-sectional, 13 cohort studies) has provided further support 
for the association of NAFLD (diagnosed by biochemistry, imaging or histology) with atherosclerosis, 
hypertension and both prevalent and incident CVD.[49] 
 
Based on the available data, there seems little doubt that NAFLD is associated with increased CVD 
prevalence, an association that has been consistently replicated across different patient populations. 
Whether NAFLD is an independent CVD risk factor or simply a bystander that shares common 
aetiological factors remains controversial.[3] However, there is a growing body of evidence 
demonstrating that CVD is a clinical concern in NAFLD, and that patients with NAFLD are more likely to 
experience a CVD-related death than a liver-related death.[4, 5] Although some studies suggested that 
only patients with NASH rather than those with simple steatosis have an increased CVD mortality 
compared with the matched control population,[50, 51] a subsequent meta-analysis brought this into 
question. In that meta-analysis patients with NAFLD (as detected by histology or ultrasonography) had 
a substantially greater risk of CVD mortality than the matched control population but presence of 
NASH did not further increase risk of CVD mortality.[52] Further prospective studies in patients with 
biopsy-characterised NAFLD are needed to address this point, although some studies with a sufficiently 
long follow-up recently showed that fibrosis stage rather than NASH best predicts long-term survival 
outcomes of NAFLD patients.[4, 5] 
 
Several studies support an association between NAFLD and incident CVD. Recent retrospective 
cohort studies reported a significant association between ultrasound-diagnosed NAFLD and the 
progression of subclinical coronary or carotid atherosclerosis independent of multiple CVD risk 
factors. The risk of subclinical carotid/coronary atherosclerosis progression was also higher among 
NAFLD patients with increased non-invasive markers of advanced fibrosis at baseline (NAFLD fibrosis 
score, fibrosis-4 score or elevated gamma-glutamyltransferase levels).[53, 54] Additionally, the 
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regression of NAFLD on ultrasound over time was associated with a decreased risk of subclinical 
carotid atherosclerosis development.[53]  
 
The presence of NAFLD at baseline, although defined clinically using the calculated fatty liver index 
(FLI), conferred an odds-ratio of 1.63 for subsequent development of carotid atherosclerotic plaques in 
a cohort of 1872 European patients.[55] Recent data also supports a bidirectional association between 
incident NAFLD and CVD risk factors. After controlling for potential confounding factors, including 
alcohol consumption, in 1051 participants of the Framingham Heart Study, individuals with NAFLD at 
baseline were more likely to subsequently develop incident hypertension and T2DM than those 
without NAFLD; conversely, those with metabolic risk factors (hypertriglyceridaemia, hypertension or 
T2DM) at baseline were more likely to develop incident NAFLD.[56] These findings are also consistent 
with natural history studies of NAFLD patients with serial liver biopsies where those with occurrence of 
incident T2DM or hypertension between biopsies were most likely to exhibit progressive liver 
fibrosis.[1, 2] A large number of observational studies also suggest that NAFLD is predictive of incident 
CVD events and death.[4, 50, 51, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67] Table 1 lists the principal 
retrospective and prospective studies that have addressed the relationship between NAFLD (defined 
radiologically or histologically) and risk of CVD events. Many of these studies were also included in an 
updated meta-analysis that incorporated a total of 16 unique, observational studies with 34043 adults 
and captured nearly 2600 CVD outcomes over a median of 6.9-year follow-up.[68] This meta-analysis 
concluded that that the presence of NAFLD (diagnosed by imaging or histology) conferred an odds-
ratio of 1.64 for fatal and non-fatal incident CVD events, a risk that appeared to increase further with 
greater severity of NAFLD and remained significant when only those studies where analysis was fully 
adjusted for potentially confounding covariates.[68] However, some of these studies have suggested 
that the increase in CVD risk may be limited to subgroups of NAFLD patients, such as those with 
advanced fibrosis,[57] T2DM [58] or men with an elevated gamma-glutamyltransferase level.[58] It is, 
therefore, conceivable that additional factors may modify the association between NAFLD and risk of 
CVD events. One such modifying factor may be genetic variation. 
 
Advances in our understanding of how genetic modifiers influence disease progression through 
genome-wide association studies are also relevant and have provided important insights into the 
cross-talk between NAFLD and CVD and how they may become dissociated.[69] Although the widely 
validated single nucleotide polymorphism, rs738409 (c.444 C>G, p.I148M) in patatin-like 
phospholipase domain-containing 3 (PNPLA3) confers an increased risk of NASH, hepatic fibrosis and 
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hepatocellular carcinoma, it has no apparent effect on CVD risk.[70, 71, 72] However, further well-
designed prospective studies are needed to better clarify this controversial issue.[70, 71, 72, 73] 
Recently, another non-synonymous genetic variant within a gene of unknown function called trans-
membrane 6 superfamily member 2, TM6SF2 (rs58542926 c.449 C>T, p.E167K), has been linked with 
NAFLD.[74] As with PNPLA3, carriage of the TM6SF2 minor (T) allele is associated with greater 
hepatic steatosis, more severe NASH and greater hepatic fibrosis/cirrhosis,[75, 76] but intriguingly, 
carriage of the more common major (C) allele promotes very-low density lipoprotein excretion, 
conferring an increased risk of dyslipidaemia and CVD.[76, 77] Thus, whilst in general NAFLD is 
associated with an increased risk of CVD, carriage of specific genetic modifiers might mean that these 
may become dissociated. In what has been described as the ‘catch-22 paradigm’, individuals that 
possess the TM6SF2 minor (T) allele will be more prone to liver-related morbidity, whilst those that 
carry the more common (C) allele may be at greater risk of CVD.[78] Whether the strength of this 
effect is sufficient to overcome the effects of many other environmental or genetic variants that 
influence outcome(s) and so be clinically relevant at an individual level does however remain to be 
definitely determined.[78] The relatively new field of epigenetics research is also providing exciting 
insights into the role of DNA methylation in the pathogenesis of NAFLD and how gene-environment 
interactions may influence CVD. [79, 80, 81, 82] 
 
Accumulating evidence also suggests that NAFLD is linked with valvular heart diseases (i.e., aortic-
valve sclerosis or mitral annulus calcification) and increased risk of cardiac arrhythmias (mainly atrial 
fibrillation and ventricular tachyarrhythmias) that may partly contribute to explain the increased risk 
of CVD events observed in patients with NAFLD.[83, 84, 85, 86, 87]  
 
Overall, therefore, the available evidence not only demonstrates the strong association between 
NAFLD and CVD but also supports the view that NAFLD increases CVD risk: a relationship that may be 
modified by a range of factors including genetic variation. This has important clinical implications 
that may influence the decision to institute primary prevention strategies with lipid-lowering, anti-
hypertensive or anti-platelet agents. At present, algorithms such as the Framingham risk equation or 
the SCORE risk charts for CVD risk assessment are used to guide initiation of preventative 
interventions. However, they are based on traditional CVD risk factors and do not include presence of 
NAFLD. Although the Framingham risk equation has been validated for use in patients with 
NAFLD,[88] it remains unclear whether the addition of NAFLD as a predictive factor in this or other 
CVD risk score systems can improve their ability to accurately predict future CVD events. Moreover, 
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randomized clinical trials with CVD outcomes that focus on treatments for liver disease in NAFLD are 
also required in order to definitely establish a causal relationship between NAFLD and risk of CVD 
events. 
 
4. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF CHRONIC KIDNEY DISEASE  
Over the past decade, several population-based and hospital-based studies have shown that the 
prevalence of CKD (defined as estimated glomerular filtration rate [eGFR]<60 ml/min/1.73 m2, 
abnormal albuminuria or overt proteinuria) was markedly increased in patients with NAFLD as 
diagnosed by imaging [89, 90, 91, 92, 93, 94, 95, 96, 97, 98] or histology.[99, 100, 101, 102, 103] In 
these studies, the prevalence of CKD ranged from approximately 20% to 55% among patients with 
NAFLD compared to 5%-30% among those without NAFLD.[89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 
100, 101, 102, 103] Notably, in most of these studies the significant association between NAFLD and 
CKD persisted after adjustment for hypertension, T2DM and other known risk factors for CKD. Pan et al. 
recently reported that after adjustment for visceral fat accumulation and other cardiometabolic risk 
factors, there was a positive, graded relationship between intrahepatic triglyceride content, as 
measured by magnetic resonance spectroscopy, and the presence of CKD or abnormal albuminuria in 
obese individuals.[97] In a population-based study of 8270 Chinese adults with normal kidney function, 
NAFLD was independently associated also with low levels of albuminuria, defined as urine 
albumin/creatinine ratio below 30 mg/g.[104] The finding of a strong association between NAFLD and 
early kidney dysfunction (i.e., microalbuminuria or eGFR<90 ml/min/1.73 m
2
) has been also 
documented in a cohort of nearly 600 overweight or obese children.[98] Recognition of this kidney 
dysfunction in childhood is clinically important because the treatment to reverse it is more likely to be 
effective if applied early in the disease process. Interestingly, some case-control studies that used liver 
biopsy to diagnose NAFLD also reported a significant, graded relationship between the severity of 
NAFLD histology and the presence of either decreased eGFR or abnormal albuminuria.[99, 100, 101, 
102, 103] For example, in a case-control study, we found that patients with biopsy-confirmed NASH 
had a greater prevalence of abnormal albuminuria and CKD than matched control subjects without 
hepatic steatosis, and that the histological severity of NASH was independently associated with 
decreasing mean eGFR values (Fig. 2).[99] That said, it is important to underline that none of the 
above-mentioned studies have used renal biopsy to examine the pathology of the CKD; so, it remains 
currently unknown if NAFLD is associated with a specific type of kidney disease (though it is very likely 
that NAFLD contributes to kidney damage mainly through accelerated atherogenesis).[89, 90, 91, 92, 
93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103]  
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Although the cross-sectional associations between NAFLD and CKD stages are strong and consistent 
across a wide range of patient populations, the data on whether NAFLD per se is causally linked to the 
development and progression of CKD remains debatable.[105, 106]  
 
In an occupational cohort of nearly 8500 non-diabetic and non-hypertensive South Korean men with 
preserved kidney function and no overt proteinuria at baseline who were followed-up for a mean 
period of 3.2 years, NAFLD (diagnosed by ultrasonography) was associated with an increased incidence 
of CKD (hazard ratio [HR] 1.60; 95% confidence interval [CI] 1.3-2.0).[107] This association remained 
significant after adjusting for body mass index, blood pressure, insulin resistance, plasma C-reactive 
protein and other potential confounding factors.[107] Similarly, in the Valpolicella Heart Diabetes 
Study, involving 1760 type 2 diabetic patients with preserved kidney function who were followed-up 
over a 6.5-year period, the presence of NAFLD on ultrasonography was associated with an increased 
incidence of CKD (HR 1.69; 95% CI 1.3-2.6) independently of traditional cardio-renal risk factors, 
diabetes-related variables and medication use.[108] Consistent with these findings, in a longitudinal 
cohort study of 261 type 1 diabetic adults with preserved kidney function at baseline, who were 
followed-up for a mean period of 5.2 years, NAFLD (diagnosed by ultrasonography) was associated 
with an approximately threefold increased incidence of CKD. Fig. 3 shows a Kaplan-Meier analysis of 
incidence curves for CKD over the follow-up period in patients with and without NAFLD at 
baseline.[109] Notably, measurement of NAFLD improved risk prediction for CKD in this patient cohort, 
independently of traditional cardio-renal risk factors (age, sex, duration of diabetes, haemoglobin A1c, 
hypertension, baseline eGFR and microalbuminuria [i.e., the last two factors being the strongest 
known risk factors for CKD]).[109]  
 
A 2014 systematic review and meta-analysis of 33 observational studies (including 20 cross-sectional 
and 13 prospective studies and involving nearly 64000 individuals) examined the relationship between 
NAFLD and risk of CKD.[110] NAFLD was diagnosed by biochemistry, imaging or histology, and CKD as 
either eGFR <60 ml/min/1.73 m2 or proteinuria. The results of this meta-analysis showed that NAFLD 
was associated with a nearly twofold increase in the prevalence and incidence of CKD. Similarly, 
although only a few studies used liver biopsy to diagnose NAFLD, the presence of histologically 
confirmed NASH was associated with an approximately 2.5-fold increased prevalence and incidence of 
CKD than simple steatosis. Moreover, the presence of advanced hepatic fibrosis was associated with a 
remarkably greater prevalence and incidence of CKD than non-advanced fibrosis. In all of these 
analyses, the significant association between NAFLD and CKD persisted after adjustment for pre-
existing diabetes, hypertension and other cardio-renal risk factors.[110]  
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In line with these observations, in a cohort of 261 patients with biopsy-proven NASH, who were 
treated with lifestyle modifications for 52 weeks, Vilar-Gomez et al. found that improvement in 
histological NASH-related endpoints, achieved by weight loss, was independently associated with 
improvement in kidney function parameters.[111] 
 
Collectively, these findings provide robust evidence of a strong association between the presence and 
severity of NAFLD with the stage and risk of developing CKD. Therefore, these findings call for a more 
active and systematic search for CKD in patients with NAFLD. However, it is important to underline 
that the quality of some of the published studies is limited, and that causality remains to be definitely 
proven in larger clinical trials with incident CKD outcomes that focus on treatments for liver disease in 
NAFLD. Notably, all these studies used creatinine-based equations to estimate GFR (which do not 
perform well in patients with cirrhosis or severe obesity) instead of direct GFR measurements to define 
CKD. Furthermore, no detailed information was available in these studies about specific renal 
pathology/morphology associated with NAFLD. Further research is also needed to better elucidate the 
underlying mechanisms by which NAFLD contributes to the development and progression of CKD.  
 
 
5. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF TYPE 2 DIABETES  
Obesity and insulin resistance are key pathogenic factors for NAFLD and T2DM, and thus these two 
diseases commonly co-exist; NAFLD is present in up to 75% of patients with T2DM, whereas the 
prevalence of T2DM in adults with NAFLD is approximately 10-18%.[112, 113, 114] In the absence of 
T2DM, NAFLD is a marker of insulin resistance independent of obesity or visceral adiposity, and 
predicts a greater deterioration in insulin sensitivity with weight gain compared to matched non-
NAFLD individuals.[115] Concomitant with these mechanistic observations, there is now robust 
evidence from observational studies demonstrating an increased risk of incident T2DM following a 
diagnosis of NAFLD. It is also notable that, in dual biopsy studies, the development of incident T2DM 
was the strongest predictor of progression to NASH and liver fibrosis.[1]  
 
A significant association between mildly elevated serum liver enzymes and increased risk of incident 
T2DM was described nearly two decades ago.[116] A meta-analysis of 20 observational studies 
(involving a total of 117000 subjects belonging to different ethnic groups) found a 1.6-2.0 fold 
increased risk of incident T2DM when comparing the highest versus the lowest quartile of serum 
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aminotransferase levels over a median follow-up of 5 years.[117] Nevertheless, serum 
aminotransferase levels are relatively insensitive markers of NAFLD. Predictive non-invasive scores, 
such as the fatty liver index or the NAFLD fatty liver score, incorporate serum liver enzymes with 
various metabolic variables, such as body mass index (BMI) and serum triglyceride levels, into their 
diagnostic algorithms, resulting in greater diagnostic accuracy for NAFLD than serum liver enzymes 
alone. Both of these non-invasive scores have been demonstrated to predict incident T2DM, 
however it is difficult to distinguish whether it is NAFLD itself or the metabolic variables within these 
scores, which are responsible for the increased T2DM risk.[118]  
 
More robust evidence of the existence of an association between NAFLD and incident T2DM arises 
from multiple large cohort studies with a median follow-up period of at least 5 years that used 
ultrasonography or, less commonly, computed tomography to diagnose NAFLD (Table 2). After 
adjusting for several potential confounding factors, NAFLD has been associated with a 1.5 to 2-fold 
increased risk of new-onset T2DM over a 5 to 10-year follow-up period.[119, 120, 121, 122, 123, 124, 
125, 126, 127, 128, 129] It is notable that the increased T2DM risk associated with NAFLD was 
observed in both sexes, however was typically higher in men, mirroring the male predominance in 
T2DM.[124, 128, 129] 
 
Notably, the risk of new-onset T2DM appears to diminish over time following the improvement or 
resolution of NAFLD, with some Asian cohort studies demonstrating T2DM incidence returning to 
that of subjects without fatty liver on ultrasonography.[129, 130, 131] This is likely to be closely 
related to temporal changes in body weight, although one study found NAFLD resolution to be 
associated with a lower incidence of T2DM independently of change in BMI.[130] Another study 
found NAFLD improvement was only associated with a reduced risk of incident T2DM in those who 
had a concomitant BMI reduction over time.[129] 
 
NAFLD appears to be additive to established metabolic risk factors of obesity and insulin resistance 
in increasing the risk of incident T2DM.[120, 127, 128, 132] One cohort study of 12853 South Korean 
non-diabetic individuals found that the risk of incident T2DM over 5 years increased 2.7 fold with a 
baseline diagnosis of fatty liver on ultrasound, and 3.7 fold with insulin resistance determined by 
homeostasis model of assessment, whereas their combination increased the risk to 6.7 fold.[132] 
Nevertheless, the interaction between insulin resistance, metabolic syndrome and NAFLD is complex 
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with several studies suggesting the association between NAFLD and incident T2DM to be modified 
by the severity of underlying insulin resistance or baseline body weight; two studies have also found 
that the risk of incident T2DM with NAFLD is limited to patients with either baseline impaired fasting 
glycaemia or those with high baseline levels of insulin resistance.[127, 133] Similarly, a Finnish study 
of hypertensive patients followed for 21 years found that NAFLD was associated with an increased 
risk of incident T2DM when co-existing with the metabolic syndrome, but not in its absence.[134] 
Surprisingly, however, two Japanese studies found the magnitude of risk of incident T2DM to be 
higher in patients who have NAFLD but are lean or have lower BMI values.[121, 128] This finding 
might be, at least in part, due to the lower sensitivity of ultrasonography for detecting NAFLD with 
increasing BMI, potentially leading to some misclassification bias. 
 
The severity of underlying NAFLD appears to influence the magnitude of future risk of T2DM, with 
increasing risk that parallels the severity of hepatic steatosis on ultrasonography or computed 
tomography.[122, 125, 126] Importantly, in these studies the T2DM risk associated with NAFLD 
remained significant even after adjustment for a range of common T2DM risk factors. Similarly, a 
Korean study found that only NAFLD patients with elevated alanine-aminotransferase levels had an 
increased risk of incident T2DM, which may reflect more severe hepatic steatosis or the 
histologically more aggressive subtype of NASH.[135] Correspondingly, patients with NASH have a 
higher risk of developing T2DM compared to those with simple steatosis, although it is not clear 
whether this risk is independent of confounding factors such as obesity.[50] Lastly, after 
stratification of NAFLD patients according to likelihood of advanced hepatic fibrosis by the NAFLD 
fibrosis score (NFS), those with high or intermediate NFS values are more than twice as likely to 
develop T2DM than those with low NFS values.[119] Although there is now convincing evidence that 
NAFLD is strongly associated with the risk of incident CKD in patients with type 1 or type 2 diabetes 
(as discussed previously), it remains unclear whether NAFLD or NASH are also independent risk 
factors for diabetic retinopathy (another microvascular complication of diabetes), with evidence 
limited only to cross-sectional studies with conflicting conclusions.[89, 136] 
 
It is important to underline that the majority of observational studies that examined the relationship 
between NAFLD and risk of incident T2DM are retrospective and originate from Asia where large 
populations undergo regular health check-ups including liver ultrasonography. Only one study from 
the United States found computed tomography-determined hepatic steatosis to be independently 
associated with increased risk of incident T2DM in a population that included Caucasians, Blacks and 
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Hispanics, however whether this risk differs according to race is unknown as a stratified analysis was 
not performed.[126] Additionally, as Asian and non-Asian populations have different adipose tissue 
distributions and cultural/genetic backgrounds, further evidence is needed in different ethnic and 
racial groups. Finally, the study by Ming et al. was the only one in which the diagnosis of diabetes 
was also based on 2-hour post-load plasma glucose levels.[123] 
 
Currently, it is unclear whether NAFLD is causally related to T2DM development or is simply a 
marker of other shared risk factors, such as visceral adipose tissue. Notably, some genetic conditions 
leading to intrahepatic triglyceride accumulation, such as familial hypobetalipoproteinemia, do not 
lead to increased insulin resistance, and genetic polymorphisms in the PNPLA3 gene (that also 
correlate with higher intrahepatic triglyceride content and increased risk of NASH, but are not 
systematically associated with insulin resistance and metabolic syndrome features) only appear to 
associate with T2DM in the presence of obesity, suggesting that other factors in addition to hepatic 
steatosis are important for the development of T2DM.[69, 137, 138]  
 
Despite the above caveats, a large number of cohort studies clearly demonstrated NAFLD to be 
associated with an approximate doubling of risk of incident T2DM. This association appears to be 
dose-dependent and is ameliorated with NAFLD improvement or resolution over time. Consequently, 
current clinical guidelines recommend routine screening of NAFLD patients for T2DM with fasting 
blood glucose or haemoglobin A1c levels or with a 75-g oral glucose tolerance test in high-risk 
groups.[139] 
 
6. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF COLORECTAL ADENOMAS/CANCER AND 
OTHER EXTRA-HEPATIC NEOPLASMS  
Patients with NAFLD typically have a range of metabolic risk factors associated with the 
development of neoplasia, including T2DM and obesity; consequently, extra-hepatic malignancy is 
the second commonest cause of death among patients with NAFLD.[4, 5] In addition, one 
community-based cohort study of T2DM patients suggested that NAFLD was associated with an 
increased risk of death from malignancy, suggesting an independent effect of NAFLD over and above 
co-existing metabolic risk factors.[140]   
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The strongest association between NAFLD and extra-hepatic neoplasia has been reported with 
colorectal adenomas (as summarized in Table 3). One Taiwanese study of 1522 individuals found a 
diagnosis of NAFLD in subjects with a normal baseline colonoscopy was associated with a 45% 
increased risk of future adenoma on subsequent colonoscopy 5 years later.[141] This association 
remained significant after adjustment for age, sex, smoking and metabolic risk factors. Two 
subsequent meta-analyses of 5 observational studies each, demonstrated a 1.5-1.7 fold increased 
risk of colorectal adenomas.[142, 143] NAFLD was also associated with multiple colorectal adenomas 
(≥3) and a tendency towards proximal lesions (right sided colonic adenomas). Whether the risk of 
colorectal adenoma increases with NASH compared to simple steatosis is unclear with two relatively 
small cross-sectional studies demonstrating conflicting results.[144, 145] Recently, a large cross-
sectional study of 26540 asymptomatic individuals from South Korea however, found the risk for any 
colorectal neoplasia and advanced colorectal neoplasia to be particularly increased in NAFLD 
patients with high NFS or other non-invasive fibrosis scores.[146] 
 
The risk of developing colorectal cancer also appears to be increased, with two large cohort studies 
of Korean and Chinese individuals undergoing colonoscopy (n=2315 and n=5517, respectively) 
finding a diagnosis of NAFLD on ultrasound to be significantly associated with an increased cancer 
risk of 1.87 (95% CI 1.4-2.6) and 3.08 (95% CI 1.02-9.3), respectively.[147, 148] Preliminary reports 
have also linked NAFLD with the occurrence of gastric and prostate cancers (reviewed in [149]), 
however further data is required before any definitive conclusions can be made. Further research is 
also needed to establish whether risk of these extra-hepatic cancers differs with severity of NAFLD. 
 
Nevertheless, the studies to date have been predominately cross-sectional, limiting any inference 
about causality and largely restricted to Asian populations. Currently, although a diagnosis of NAFLD 
is not sufficient to recommend screening colonoscopy, however evaluation of colonic symptoms and 
ensuring patients are enrolled in colorectal cancer screening programs as per recommendations for 
the general population is strongly recommended. Further evidence is needed to clarify the risk in 
patients aged 40-50 years of age who are not currently within routine screening guidelines. However, 
if the potential adverse impact of NAFLD on risk of colorectal adenomas/cancer will be confirmed in 
future large-scale prospective studies, there may be significant implications for screening and 
surveillance strategies given the growing number of NAFLD patients. 
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7. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF OSTEOPOROSIS  
NAFLD is associated with multiple factors linked to decreased bone mineral density (BMD), including 
T2DM, obesity, insulin resistance, chronic inflammation, vitamin D3 deficiency and low levels of 
physical activity.[150] Consequently, several cross-sectional and case–control studies involving both 
adults and adolescents have found a significant association between low BMD or osteoporosis and 
NAFLD (reviewed in [150]). Worryingly, this association has been also reported in the paediatric age 
group, with one study of 38 obese children with biopsy-proven NAFLD reporting significantly lower 
BMD compared to 38 non-steatotic children matched for age, sex, ethnicity and BMI.[151] The 
degree of BMD fell with increasing severity of liver disease with patients with NASH having a lower 
level than those with simple steatosis.  
 
In adults, the association between NAFLD and osteoporosis is less consistent, with a meta-analysis of 
a total of 1276 individuals finding no significant differences in BMD between subjects with or 
without NAFLD, whereas a significant association with BMI was found.[152] Significant 
heterogeneity between studies however, limits conclusions from this meta-analysis. Subsequently, 
three large cohort studies totalling over 2500 individuals, all found a significant inverse association 
between BMD and NAFLD, although interestingly the association was limited to males and not seen 
in post-menopausal females.[153, 154, 155] The association between NAFLD and BMD was modest, 
however remained significant in these studies even after adjusting for several potential confounding 
factors, including age, weight, alcohol intake, smoking and metabolic risk factors. Increasing 
ultrasonographic severity of hepatic steatosis as well as serum alanine-aminotransferase levels 
correlated inversely with BMD.[153] A further cohort study of 7797 Chinese adults aged >40 years 
confirms the existence of a sex-specific association with a higher rate of recent osteoporotic 
fractures in males with NAFLD compared to those without (3.6% vs. 1.7%, p=0.003), with no 
difference seen in females.[156] Overall, males with NAFLD had a 2.5-fold increased risk of recent 
osteoporotic fractures even after adjustment for age, smoking, alcohol intake, physical activity, 
metabolic risk factors, kidney function and use of glucocorticoids or osteoporosis medications.[156] 
The male specific association suggests a sex-specific interaction between hepatic steatosis and bone 
metabolism, or that other factors in females, such as oestrogen status, may dominate the risk of 
osteoporosis.  
 
Collectively, these findings argue for awareness of BMD among patients with NAFLD. However, it is 
important to note that the available data is limited to cross-sectional studies largely from Asian 
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populations. The majority of studies focus on BMD rather than bone fracture rate and further 
evidence is required to clarify whether NAFLD patients (in particular males) should be screened for 
osteoporosis.  
 
8. PUTATIVE MECHANISMS LINKING NAFLD TO EXTRA-HEPATIC CONDITIONS  
Extra-hepatic pathologic conditions in NAFLD are closely linked to the presence of local (i.e., in the 
liver, adipose tissue, vessels and heart) and systemic inflammation. Chronic low-grade inflammation 
accompanies many metabolic disorders, such as T2DM or NAFLD.[157] It has been demonstrated 
that inflammatory pathways such as interleukin-1 type cytokines are driving forces of disease 
processes in NAFLD and correlate with prognosis of liver disease.[158, 159] Hepatic inflammation 
might not only be responsible for the overall degree of hepatic fibrosis and thereby prognosis of this 
disorder but might also control insulin resistance. Hepatic/peripheral insulin resistance (i.e., a 
hallmark in most patients with NAFLD) and metabolic inflammation are frequently observed in 
parallel, and research from the past has tried to connect these two phenomena.[160] The origin of 
chronic inflammatory processes observed in NAFLD is still a matter of discussion as multiple parallel 
‘hits’ might control and regulate disease process.[161] Besides lipotoxicity, the gastrointestinal tract 
with its significantly altered microbiota could reflect one of the early events in disease development. 
In addition, abdominal visceral adipose tissue accumulation is another ‘hot’ candidate reflecting a 
major site of chronic inflammation in NAFLD as adipose tissue inflammation is commonly observed 
in obesity, T2DM and NAFLD. Indeed, it has been shown that the inflamed (‘dysfunctional’) adipose 
tissue in obesity might generate almost 50% of circulating interleukin-6 thereby contributing 
substantially to systemic chronic inflammation.[162] The importance of visceral adipose tissue as 
site of chronic inflammation is further supported by some studies demonstrating that the lack of 
adipocyte 5' AMP-activated protein kinase worsens insulin resistance and liver disease by affecting 
brown and beige adipose tissue function.[163] Additionally, adipose tissue-specific insulin receptor 
knockout mice develop more severe NAFLD with histological evidence of ballooning degeneration 
further supporting the notion that the adipose tissue is of key importance in the development and 
progression of NAFLD.[164] In contrast, recent research has found that adipose tissue type I 
interferon signalling may protect from metabolic dysfunction.[165] 
 
8.1 Nutrition and dietary factors 
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Nutrition is critically involved in the pathogenesis of NAFLD besides from the fact that NAFLD is 
mainly a disease of the obese population. Over-nutrition and certain dietary factors have been 
demonstrated to induce chronic low-grade inflammation.[166, 167] Epidemiologic studies have 
shown that diet can affect inflammatory processes and the immune system directly, and also 
through interactions with the gut microbiota. Western diets are able to promote chronic 
inflammatory processes by many pathways. A high salt content may induce interleukin-17 producing 
T-helper cells and thereby inflammation.[168] Dietary fatty acids promote inflammation through 
several mechanisms, including direct effects on immune cells, activation of toll-like receptors and 
cytokine cascades [169] and affecting intestinal permeability.[170] Mice with a loss of junctional 
adhesion molecule A (JAM-A) have a defect intestinal epithelial barrier and exhibit more prominent 
NASH, and colonic tissue from patients with NAFLD have lower levels of JAM-A and higher levels of 
inflammation compared to healthy controls.[171] In healthy individuals, a high-fat Western diet 
induces endotoxinaema and, therefore, might contribute to the observed chronic inflammation in 
NAFLD.[172] A diet rich in saturated milk-derived fatty acids worsens colitis in interleukin-10 
deficient mice via profound changes of the gut microbiota and an increased T-helper 1 cell 
response.[173] Many studies have also associated dietary phosphatidylcholine and L-carnitine 
consumption with generation of specific metabolites (i.e., trimethylamine [TMA] and TMA N-oxide 
[TMAO]) and future CVD events.[174] Not surprisingly, dietary interventions might be able to 
reverse a Western-diet induced liver phenotype as shown e.g. for citrulline.[175] Overall, the 
composition of Western diets might not only contribute to the development/progression of NAFLD 
via generation of overweight and obesity, but also induce activation of specific inflammatory 
pathways. 
 
8.2 Gut microbiota 
Evidence is increasing that the gut microbiota might contribute to the pathogenesis of NAFLD. 
NAFLD reflects a prototypic disease of innate immunity and it is expected that certain bacteria in the 
intestinal tract activate various pathways of innate immunity in the case of disease.[176] In several 
mouse models, the microbiota affects hepatic steatosis and fat storage. Human studies from the 
past years have also supported a role for the microbiota in NAFLD. Actinobacteria were increased 
whereas Bacteroidetes were reduced dependent on liver disease activity as demonstrated in a 
paediatric study population.[177] At species levels, Oscillobacter decreased in NAFLD whereas 
Ruminococcus, Blautia, and Dorea increased especially in patients with NASH.[177] Another study 
assessed the gut microbiota and severity of histology-proven NAFLD in 57 patients.[178] Bacteroides 
Page 21 of 85
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 19
abundance increased depending on severity of disease, whereas Prevotella abundance decreased. 
Ruminococcus abundance increased in more severe disease, especially if advanced hepatic fibrosis 
was diagnosed.[178] Overall, many studies from the past years clearly highlighted a role for the gut 
microbiota in obesity-related disorders supporting the assumption that NASH might be associated 
with a “microbiome signature” which could contribute to initiation of inflammation. It has to be 
acknowledged, however, that these early studies are rather descriptive and neither studies (either 
preclinical or clinical) have so far identified certain bacterial strains, which act pro-inflammatory and 
are indeed involved in disease pathogenesis. The altered microbiome in patients with NAFLD could 
also be involve  in the development of NAFLD-associated malignancy both in the liver [179] and in 
the gastrointestinal tract.[180] 
 
8.3 Cytokines/adipocytokines 
It is well established that proinflammatory cytokines and transcription factors are highly expressed 
in various tissues, such as the adipose tissue or liver, in NAFLD and a large number of different 
immune cells and, especially, tissue macrophages may contribute to the inflammatory phenotype. 
Various proinflammatory cytokines, such as TNF-alpha or interleukin-6, are activated in different 
tissues but especially, in adipose tissue and in the liver of patients with NAFLD/NASH.[181] There is 
substantial evidence that activation of the transcription of nuclear factor–kappa B (NF-κB) and 
downstream inflammatory signalling pathways are involved in metabolic liver inflammation and 
associated hepatic insulin resistance.[182, 183] Receptor activator of NF-κB (RANKL), a prototypic 
activator of NF-κB, regulates hepatic insulin sensitivity.[184] Deletion of hepatic MyD88 results in 
liver inflammation and hepatic insulin resistance also affecting the gut microbiota composition and 
metabolome.[185] Therefore, several studies using hepatocyte-specific targeting of genes have now 
strongly supported the notion that hepatocytes are major metabolic “players” in the development of 
metabolic inflammation in and beyond the liver. 
 
Chronic inflammation and cytokine activation is a driving force in the evolution of malignancy and, 
therefore, it is expected that patients with NAFLD exhibit a high rate of liver and extra-hepatic 
malignancies.[144, 186] Chronic interleukin-6 over-expression has been found to result in the 
generation of liver tumours.[187] In these studies, the development of obesity-promoted 
hepatocellular carcinoma was dependent on enhanced production of the tumour-promoting 
cytokines interleukin-6 and TNF-alpha, which cause hepatic inflammation and activation of the 
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oncogenic transcription factor STAT3. Besides several cytokines also certain adipocytokines, such as 
adiponectin and leptin, might contribute to systemic inflammatory processes and associated 
pathologies in NAFLD.[188, 189] For example, NAFLD is associated with hypoadiponectinaemia and 
lower adiponectin levels correlate with colorectal cancer/adenoma incidence.[190, 191] Low-level 
plasma adiponectin is especially associated with KRAS-mutant colorectal cancer risk.[192] Therefore, 
it may be concluded that chronic activation of cytokine/adipocytokine cascades as observed in 
NAFLD might contribute substantially to the extra-hepatic chronic diseases observed in NAFLD 
ranging from CVD to osteoporosis and especially also hepatic and extra-hepatic cancers.  
 
9. CONCLUSIONS  
This review further reinforces the view that NAFLD is a multisystem disease that affects many extra-
hepatic organ systems and interacts with the regulation of multiple metabolic pathways. NAFLD is 
associated not only with liver-related morbidity and mortality, but also with an increased risk of 
developing important extra-hepatic chronic diseases, such as CVD, T2DM and CKD. Emerging data 
also suggests NAFLD may be a risk factor for colonic adenomas/cancer and decreased bone mineral 
density, particularly among men. Clear evidence indicates that CVD is the leading cause of death in 
patients with NAFLD. This implies that patients with NAFLD should undergo careful cardiovascular 
surveillance. In line with this implication, given that CVD complications dictate the outcome(s) in 
patients with NAFLD more frequently and to a greater extent than does the progression of liver 
disease, the recent European clinical practice guidelines have recommended CVD risk assessment in 
all patients with NAFLD.[139]  
 
There is a growing body of epidemiological and experimental evidence suggesting that NAFLD, 
especially its necro-inflammatory form, exacerbates hepatic/peripheral insulin resistance, 
predisposes to atherogenic dyslipidaemia and releases a variety of proinflammatory, procoagulant, 
thrombogenic and profibrogenic factors that may promote the development of CVD, CKD, T2DM and 
other extra-hepatic chronic diseases. 
 
However, although all these mechanisms plausibly link NAFLD to the development and progression 
of CVD, CKD and other extra-hepatic diseases, no studies to date have proven a cause-and-effect 
relationship and further research is certainly needed to gain mechanistic insights into the 
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pathophysiology linking NAFLD to the development and progression of these extra-hepatic chronic 
diseases. 
 
In the meantime, we believe that the clinical implication of these findings is that a diagnosis of 
NAFLD may identify a subset of the general population, which is exposed to an increased risk of 
developing some important extra-hepatic chronic diseases. Therefore, patients with NAFLD might 
benefit from more intensive surveillance or early treatment interventions to decrease the risk of 
developing CVD, CKD, T2DM and other extra-hepatic manifestations. Thus, clinicians who manage 
patients with NAFLD, especially those with NASH with varying amounts of fibrosis, not only should 
focus on liver disease, but also should recognize the increased risk of CVD, CKD, T2DM and other 
serious extra-hepatic manifestations of these patients, screen them for conventional risk factors and 
undertake early, aggressive risk factor modification(s). 
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FIGURE LEGENDS 
 
Figure 1. Nonalcoholic fatty liver disease: a multisystem disease.  
Reported associations between NAFLD and various human diseases. 
 
Figure 2. Kidney function in patients with non-alcoholic steatohepatitis. 
Panel A shows the prevalence of both abnormal albuminuria (i.e., urinary albumin-to-creatinine 
ratio≥30 mg/g) and chronic kidney disease (CKD; defined as eGFRMDRD <60 ml/min/1.73 m
2 or abnormal 
albuminuria) in 80 overweight patients with biopsy-proven NASH and 80 non-steatotic control 
individuals who were matched for age, sex and body mass index. Panel B shows the adjusted means 
(±standard deviations) of estimated glomerular filtration rate in patients with NASH according to the 
histologic stage of hepatic fibrosis (from 0, indicating no fibrosis, to 3, indicating advanced fibrosis; 
patients with cirrhosis [i.e., those with stage 4 fibrosis] were not included in the study). Data have 
been adjusted for age, sex, body mass index, waist circumference, hypertension status, plasma 
triglyceride concentrations, and insulin resistance (as estimated on the basis of a homeostasis model 
assessment). Data are from Targher et al.[99] Reproduced with permission. 
 
Figure 3. Risk of incident chronic kidney disease in patients with type 1 diabetes and non-alcoholic 
fatty liver disease. 
Incidence curves for CKD (defined as occurrence of estimated glomerular filtration rate [eGFR]<60 
ml/min/1.73 m
2
 or macroalbuminuria) in a cohort of 261 type 1 diabetic adults with (dotted line) and 
without (solid line) NAFLD on ultrasonography over a mean follow-up period of 5.2 years. All patients 
had preserved kidney function (eGFRMDRD≥60 ml/min/1.73 m
2) and no macroalbuminuria at baseline. 
Patients with known liver diseases and those with a prior history of cardiovascular disease were 
excluded from the study. Data are from Targher et al.[109] Reproduced with permission. 
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TABLE 1. Selected observational studies exploring the risk of CVD in patients with NAFLD as diagnosed by histology or imaging (studies were ordered by 
methodology of NAFLD diagnosis and publication year). 
Authors,  
Year [ref.] 
Study  
Population 
Follow-up 
Length  
NAFLD  
Diagnosis 
Study  
Outcomes 
Main  
Findings  
Matteoni CA et al., 
1999 [61] 
Retrospective cohort of 132 US patients with 
NAFLD and raised serum liver enzymes 
18 years Histology All-cause and cause 
specific mortality 
Patients with NASH had higher rates of all-cause and 
liver-related mortality than those without. CVD death 
rate did not differ between the groups 
Dam-Larsen S et al., 
2004 [62]  
Retrospective cohort of 109 Danish patients 
with nonalcoholic simple steatosis (without 
NASH at baseline) 
16.7 years Histology All-cause and cause specific 
mortality 
No significant difference in death rates between 
patients with simple steatosis and the general 
population 
Adams LA et al. 2005 
[64]  
Retrospective community-based cohort of 420 
US patients with NAFLD  
7.6 years Histology & 
Imaging 
All-cause and cause specific 
mortality 
Patients with NAFLD (especially those with cirrhosis 
and NASH) had higher rates of all-cause, CVD and 
liver-related mortality than the matched general 
population 
Ekstedt M et al. 2006 
[50] 
Retrospective cohort of 129 Sweden patients 
with NAFLD and raised serum liver enzymes 
13.7 years Histology All-cause and cause 
specific mortality 
Patients with NASH, but not those with simple 
steatosis, had higher rates of all-cause (~2 fold), CVD 
(~2 fold) and liver-related (~10 fold) mortality than 
the reference population 
Rafiq N et al. 2009 [63] Retrospective cohort of 173 US patients with 
NAFLD and raised serum liver enzymes 
13 years Histology All-cause and cause 
specific mortality 
CVD, malignancy and liver-related complications were 
the most common causes of mortality 
Söderberg C et al. 2010 
[51]  
Retrospective cohort of 118 Sweden patients 
with NAFLD and raised serum liver enzymes 
24 years Histology All-cause and cause specific 
mortality 
Patients with NASH, but not those with simple 
steatosis, had higher rates of all-cause (~2 fold), CVD 
(~2 fold) and liver-related mortality than the matched 
general population 
Ekstedt et al. 2015 [4] Retrospective cohort of 229 Sweden patients 
with biopsy proven NAFLD 
26.4 ± 5.6 
years 
Histology All cause and disease-
specific mortality 
NAFLD patients have increased overall mortality (HR 
1.29, 95% CI 1.04-1.59), with a high risk of death from 
CVD (HR 1.55, 95% CI 1.11-2.15) and liver-related 
disease. Stage of fibrosis rather than presence of NASH 
predicted both overall and disease-specific mortality 
Fracanzani et al. 2016 
[193] 
Prospective case-control study of 125 Italian 
patients with NAFLD and 250 age- and sex-
matched control individuals without known liver 
diseases 
10 years Histology & 
Ultrasound 
Non-fatal CVD events 
(acute coronary syndrome, 
coronary revascularization 
procedures, ischemic stroke 
or transitory ischemic 
attacks as combined 
endpoint) 
NAFLD was independently associated with incident 
nonfatal CHD events  (HR 1.99, 95% CI 1.01-3.91) 
Jepsen P et al. 2003 
[65] 
Retrospective cohort of 1,800 Danish patients 
discharged with a hospital diagnosis of NAFLD  
6.2 years Ultrasound & 
Liver enzymes 
All-cause and cause 
specific mortality 
Patients with NAFLD had higher rates of all-cause (2.6 
fold), CVD (2.1 fold) and liver-related (19.7 fold) 
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mortality than the general population 
Hamaguchi M et 
al.[59]   
Community-based cohort of 1,637 Japanese 
apparently healthy individuals  
5 years Ultrasound Non-fatal coronary heart 
disease and stroke 
NAFLD was independently associated with increased 
risk of nonfatal CVD events (HR 4.10, 95% CI 1.6-10.7) 
Targher G et al. 2007 
[45]   
Prospective cohort of 2,103 Italian type 2 
diabetic individuals without baseline viral 
hepatitis and CVD 
6.5 years Ultrasound CVD mortality and non-
fatal   myocardial 
infarction, ischemic stroke 
and revascularization 
procedures (combined 
endpoint) 
NAFLD was independently associated with increased 
risk of fatal and non-fatal CVD events (HR 1.87, 95% CI 
1.2-2.6) 
Haring R et al. 2007 
[58]   
Population-based cohort study of 4,160 German 
adult men and women without baseline viral 
hepatitis or cirrhosis 
7.3 years Ultrasound All-cause and cause 
specific mortality 
NAFLD was independently associated with increased 
risk of all-cause and CVD mortality in men (HR 6.2, 
95% CI 1.2-31.6) 
Zhou J et al. 2012 [67]   Community-based cohort study of 3,543 
Chinese adult men and women  
4 years Ultrasound All-cause and cause 
specific mortality 
Patients with NAFLD had ~3-fold higher rates of all-
cause and CVD mortality than those without NAFLD 
Stepanova M et al. 
2013 [43] & Lazo M et 
al. 2011 [44] 
National-based cohort study of 11,371 US adult 
participants from the Third National Health and 
Nutrition Examination Survey 1988-94  
14.5 years Ultrasound  All-cause and cause 
specific mortality 
No significant association between NAFLD and all-
cause and cause specific mortality 
Pisto et al. 2014 [60] Population-based, randomly recruited cohort of 
988 middle-aged Finnish participants 
~18 years Ultrasound Fatal and non-fatal CVD 
events  
Severe NAFLD did not significantly predict the risk of 
CVD events after adjustment for potential 
confounders, including insulin resistance 
Wong VW et al. 2016 
[48] 
612 consecutive Chinese patients undergoing 
coronary angiograms without known liver 
diseases 
6 years Ultrasound  Fatal and non-fatal CVD 
events, heart failure or 
secondary coronary 
interventions (combined 
endpoint) 
NAFLD patients, compared with those without, were 
more likely to have >50% stenosis in one or more 
coronary arteries and therefore require percutaneous 
coronary intervention. NAFLD was not significantly 
associated with fatal and non-fatal CVD events 
Mantovani et al. 2016 
[194] 
Retrospective cohort of 286 Italian type 1 
diabetic adults without known liver diseases 
5.3 ± 2 years Ultrasound Non-fatal ischemic heart 
disease, nonfatal ischemic 
stroke or 
coronary/peripheral artery 
revascularization 
procedures (combined 
endpoint) 
NAFLD was independently associated with an 
increased risk of non-fatal CVD events (HR 6.73, 95% CI 
1.2-38) 
Treeprasertsuk S et al. 
2012 [195] 
Community-based cohort of 309 US patients 
with NAFLD  
11.5±4.1 
years 
Ultrasound & 
Computed 
tomography 
New-onset CVD NAFLD patients have a higher 10-year CHD risk than 
the general population of the same age and sex 
Kim et al. 2013 [57] National-based cohort study of 11,154 US adult 
participants from the Third National Health and 
Nutrition Examination Survey 1988-94 
14.5 years Ultrasound & 
Non-invasive 
fibrosis markers 
(NFS/APRI/FIB4) 
All-cause and cause specific 
mortality 
NAFLD not associated with increased mortality. 
However, advanced fibrosis, as determined by non-
invasive fibrosis markers, is a significant predictor of 
mortality, mainly from CVD causes, independent of 
other known factors 
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Zeb et al. 2016 [196] Prospective cohort study of 4119 US adult 
participants who were free of CVD and known 
liver diseases at baseline (The Multi-Ethnic Study 
of Atherosclerosis) 
7.6 years 
(median) 
Computed 
tomography 
All-cause mortality and CVD 
events (myocardial 
infarction, resuscitated 
cardiac arrest, angina or 
coronary revascularization 
procedures) 
NAFLD was independently associated with incident 
CHD events (HR 1.42, 95% CI 1.00-2.03) 
Abbreviations: CHD=coronary heart disease, CVD=cardiovascular disease; HR=hazard ratio; CI=confidence intervals; T2DM=type 2 diabetes mellitus.  
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TABLE 2. Retrospective or prospective cohort studies examining NAFLD (as detected either by ultrasonography or by computed tomography) as a risk 
factor for incident type 2 diabetes mellitus. 
Authors, 
Year [ref.] 
Country Sample 
Size 
Follow-up 
(median, 
years) 
T2DM Diagnosis T2DM% at Follow-up Adjusted Odds Ratio(s)  
(±95% CI) 
Adjusted Variables 
Okamoto et 
al.  
2003[124] 
Japan 840 10.0 FBG ≥140 mg/dl (≥7.8 mmol/l) or 
HbA1c ≥6.5% or T2DM 
medications 
14.1% (males) 4.3% 
(females) 
1.8  
(0.9-3.5) 
Age, sex, BMI, weight gain, FBG, HbA1c, alcohol intake, 
family history of diabetes 
Kim et al.  
2008[122] 
South Korea 5372 5.0  FBG ≥126 mg/dl (≥7.0 mmol/l) or 
T2DM medications or past history 
4.3% 1.5  
(1.1-2.2) 
Age, sex, BMI, smoking, family history of diabetes, ALT, 
FBG, triglycerides, HDL-cholesterol 
Yamada et 
al. 
2010[128] 
Japan 12375 5.0 FBG ≥126 mg/dl or T2DM 
medications 
1% (males) 1.9 (1.9-2.8) males Age, BMI, blood pressure, alcohol intake, smoking 
 0.5% (females) 2.1 (2.5-4.7) females 
Sung et al.  
2011[127] 
South Korea 11091 5.0 Not reported 1.6% 2.05  
(1.35-3.12) 
Age, sex, BMI, alcohol, education, smoking, exercise 
Chang et al.   
2013[119] 
South Korea 38291 5.1 FBG ≥126 mg/dl or HbA1c ≥6.5% 
or T2DM medications 
1.1% annual 
incidence 
2.0 (1.8-2.2) for low NFS 
4.7 (3.7-6.1) for 
intermediate/high NFS 
Sex, smoking, alcohol intake, exercise, family history of 
diabetes, total cholesterol, triglycerides, HDL-
cholesterol, CRP, HOMA-insulin resistance 
Park et al.  
2013 [125] 
South Korea 25232 
(men) 
5.0 FBG ≥126 mg/dl or HbA1c ≥6.5% 
or T2DM medications or past 
history 
8.4% 1.73 (1.00-3.01) Age, waist circumference, triglycerides, HDL-cholesterol, 
CRP, HOMA-insulin resistance, creatinine, blood 
pressure, family history of diabetes, exercise, MetS 
Shah et al.  
2015 [126] 
USA 3153 9.1 FBG ≥126 mg/dl or T2DM 
medications or past history 
6.9% 2.06 (1.52-2.79)* Age, sex, race, BMI, waist circumference, family history 
of diabetes, blood pressure, FBG, HDL-cholesterol, 
triglycerides, exercise, CRP, statin use 
Yamakazi et 
al. 
2015[129] 
Japan 4604 11.3 FBG ≥126 mg/dl or HbA1c ≥6.5% 
or T2DM medications or past 
history 
6.1% 2.37 (1.60-3.52) Age, sex, BMI, impaired fasting glycaemia, family history, 
dyslipidaemia, blood pressure, exercise 
Ming et al.  
2015[123] 
China 508 5.0 FBG ≥126 mg/dl or 2-h OGTT 
≥200 mg/dl or T2DM medications  
3.9% 4.46 (1.86-10.73) Age, sex, BMI, education, smoking, alcohol intake, 
exercise, family history, blood pressure, FBG, HDL-
cholesterol, triglycerides 
Chen et al.  
2016[120] 
China 6542 6.0 FBG ≥126 mg/dl or T2DM 
medications or past history 
5.6% 2.17 (1.53-3.01)* Age, BMI, triglycerides, impaired fasting glycaemia status 
Fukada et al.  
2016[121] 
Japan 4629 12.8 FBG ≥126 mg/dl or HbA1c ≥6.5% 
or T2DM medications 
7.6% 3.6 (2.1-5.8) for lean 
6.8 (5.2-8.9) for obese 
Age, sex, smoking, alcohol intake, exercise, HbA1c, 
family history of diabetes 
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Footnote: Only cohort studies with a median follow-up period of at least 5 years are presented. The study by Shah et al. is the only one in which the diagnosis of NAFLD was based on 
computed tomography. The study by Ming et al. is the only one in which the diagnosis of diabetes mellitus was also based on 2-hour OGTT glucose levels *Hazard ratio presented.   
Abbreviations: T2DM=type 2 diabetes mellitus; BMI=body mass index; FBG=fasting blood glucose; HbA1c=haemoglobin A1c; ALT=alanine aminotransferase; OGTT=oral glucose tolerance test; 
HDL=high-density lipoprotein; HOMA=homeostasis model assessment; CRP=C-reactive protein; MetS=metabolic syndrome; NFS=NAFLD fibrosis score. 
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TABLE 3. Cohort studies examining NAFLD as a possible risk factor for colorectal neoplasia. 
Authors, 
Year [ref.] 
Country Study 
Design 
Sample 
Size 
Follow-up 
(median, 
years) 
Adenoma (%) Carcinoma (%) Adjusted Odds Ratio(s)  
(±95% CI) 
Adjusted Variables 
Non-NAFLD NAFLD Non-NAFLD NAFLD  Adenoma Carcinoma 
Hwang et al. 
2010[197] 
South 
Korea 
Cross-
sectional 
2917 NA 16% 24% - - 1.28 
(1.03-1.60) 
- Age, sex, smoking, T2DM, blood 
pressure, MetS 
Touzin et al.  
2011[145] 
USA Cross-
sectional 
233 NA 25% 24% - - - - - 
Wong et al. 
2011[144] 
Hong Kong Cross-
sectional 
380 NA 22% 35% 0.6% 1% 1.61 
(0.90-2.90) 
- Age, sex, BMI, smoking, family 
history, blood pressure, T2DM, 
aspirin use 
Stadlmayr 
et al. 
2011[198] 
Austria Cross-
sectional 
1211 NA 17% 28% 0.1% 0.9% 1.47  
(1.08-2.00) 
- Age, sex, BMI, glucose intolerance 
status 
Lin et al. 
2014 [148] 
China Cross-
sectional 
2315 NA 56% 44% 18% 29% 0.86  
(0.61-1.20) 
1.87 
(1.36-2.57) 
Age, sex, smoking, BMI, alcohol 
intake, T2DM, blood pressure, 
lipids, serum liver enzymes 
Bhatt et al. 
2015[199] 
USA Cross-
sectional 
591
$ 
NA 21% 32% 0% 0% 1.95 
(1.09-3.48) 
- Age, ethnicity, BMI, blood 
pressure, alcohol intake, smoking, 
MELD or Child-Pugh classes 
Basyigit et 
al. 
2015[200] 
Turkey Cross-
sectional 
127 NA 26% 20% 24% 5% 0.63 
(0.46-1.65) 
0.13 
(0.12-0.31) 
Age, sex, obesity, T2DM, MetS 
Ahn et al. 
2017[146] 
South 
Korea 
Cross-
sectional 
26540 NA 29% 38% - - 1.10  
(1.03-1.17) 
- Age, sex, BMI, smoking, alcohol 
intake, family history, aspirin use, 
MetS factors 
Lee et al. 
2012[147] 
South 
Korea 
Cohort 5517 
(women) 
7 years - - - - 1.94  
(1.11-3.40) 
3.08 
(1.02-9.34) 
Age, smoking, MetS  
Huang et al. 
2013[141] 
Taiwan Cohort 1522* 5 years 39% 56% - - 1.45  
(1.07-1.98) 
- Age, sex BMI, smoking, blood 
pressure, T2DM, MetS 
Footnote: *All had negative baseline colonoscopy. 
$
All patients being evaluated for liver transplantation.  
Abbreviations: T2DM=type 2 diabetes; BMI=body mass index; MetS=metabolic syndrome; NA=not applicable.
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List of Abbreviations 
BMD, bone mineral density  
BMI, body mass index 
CI, confidence interval 
CKD, chronic kidney disease 
CVD, cardiovascular disease 
eGFR, estimated glomerular filtration rate 
HR, hazard ratio 
JAM-A, junctional adhesion molecule A  
NAFLD, nonalcoholic fatty liver disease 
NASH, nonalcoholic steatohepatitis 
NF-κB, nuclear factor–kappa B  
NFS, NAFLD fibrosis score  
OR, odds ratio 
PNPLA3, patatin-like phospholipase domain-containing 3  
RANKL, receptor activator of nuclear factor–kappa B 
T2DM, type 2 diabetes mellitus 
TM6SF2, trans-membrane 6 superfamily member 2  
TMA, trimethylamine  
TMAO, trimethylamine-N-oxide 
TNF, tumour necrosis factor 
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1. ABSTRACT  
Key physiological functions of the liver, including glucose and lipid metabolism, become disturbed in 
the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated with a systemic 
inflammatory ‘milieu’ initiated in part by liver-secreted cytokines and molecules. Consequently, the 
pathophysiological effects of NAFLD extend beyond the liver with a large body of clinical evidence 
demonstrating NAFLD to be independently associated with both prevalent and incident cardiovascular 
disease (CVD), chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). The magnitude of 
risk of developing these extra-hepatic diseases parallels the underlying severity of NAFLD, such that 
patients with non-alcoholic steatohepatitis (NASH) appear to be at greater risk of incident CVD, CKD 
and T2DM than those with simple steatosis. Other modifiers of risk may include genetic variants [e.g., 
patatin-like phospholipase domain-containing 3 (PNPLA3) and trans-membrane 6 superfamily member 
2 (TM6SF2) polymorphisms], visceral adipose tissue accumulation, dietary intake and the gut 
microbiome. Emerging data also suggest that NAFLD may be a risk factor for colonic neoplasia and 
reduced bone mineral density, especially among men. Importantly, improvement/resolution of NAFLD 
is associated with a reduced incidence of T2DM and improved kidney function, adding weight to 
causality and suggesting liver focused treatments may reduce risk of extra-hepatic complications. 
Awareness of these associations is important for the clinicians such that CVD risk factor management, 
screening for T2DM and CKD are part of the routine management of patients with NAFLD.   
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2. INTRODUCTION  
Non-alcoholic fatty liver disease (NAFLD) is a very common pathologic condition worldwide that is 
closely associated with the clinical features of metabolic syndrome and is characterised by substantial 
inter-patient variability in severity and rate of liver disease progression.[1, 2]  
 
A purely liver-centric view is that NAFLD represents a spectrum of progressive liver disease occurring in 
the absence of excessive alcohol consumption that ranges from isolated intrahepatic triglyceride 
accumulation (simple steatosis); through intrahepatic triglyceride accumulation plus inflammation and 
hepatocyte injury (nonalcoholic steatohepatitis, NASH); and ultimately progresses to fibrosis/cirrhosis 
and potentially hepatocellular carcinoma.[3] Although a significant proportion of the population have 
NAFLD, only a minority progress to advanced liver disease or liver-related death.[3]  
 
However, this liver-centric view does not encompass the wider ramifications of NAFLD. Indeed, NAFLD 
is just one facet of a multisystem disease (Fig. 1) that confers substantially increased morbidity and 
mortality on those patients who are affected and where the most common causes of death are 
cardiovascular disease (CVD), followed by extra-hepatic malignancies and liver-related 
complications.[4, 5]  
 
This review mainly focuses on the principle extra-hepatic chronic diseases associated with NAFLD 
where there is now strongest evidence for a potential causal link: CVD, T2DM, chronic kidney disease 
[1, 2] and, to a lesser extent, certain types of extra-hepatic tumours and osteoporosis.  
 
 
3. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF CARDIOVASCULAR DISEASE  
That NAFLD is associated with an increased risk of CVD is unsurprising, given the close associations 
between NAFLD and the established CVD risk factors encapsulated by the metabolic syndrome, 
including abdominal obesity, hypertension, atherogenic dyslipidaemia and insulin 
resistance/dysglycaemia.[6, 7, 8] Highlighting the intimacy of these associations is the observation 
that the increases in hepatic lipid accumulation are directly proportional to the severity of each 
component of the metabolic syndrome.[9] However, the nature and extent of these associations, 
whether simply due to a shared underlying aetiology or because the presence of NAFLD confers an 
additional risk, remains the subject of much scrutiny. This attention is undoubtedly warranted as it 
has important clinical implications for screening and surveillance strategies in the growing number of 
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patients with NAFLD. Addressing CVD risk in patients with NAFLD is also the aspect of the disease 
most amenable to medical management and so improving long-term clinical outcomes.  
 
Beyond the associations with traditional CVD risk factors, patients with NAFLD also exhibit a range of 
non-traditional CVD risk factors, including hyperuricaemia,[10, 11, 12] hypoadiponectinaemia [13, 14, 
15] and hypovitaminosis D.[16] The association with CKD, discussed later in this review, also confers 
an increased risk of CVD.[17] Other potentially contributing risk factors include increased levels of 
circulating proinflammatory markers (e.g., C-reactive protein, interleukin-6, tumour necrosis factor-
alpha and other hepatic acute-phase proteins), procoagulant factors (e.g., fibrinogen and 
plasminogen activator inhibitor-1) and adhesion molecules (e.g., vascular adhesion protein-1) that 
are likely to have been synthesised within the liver, especially in the presence of NASH.[18, 19, 20, 
21, 22, 23] 
 
Substantial epidemiological evidence links NAFLD with objectively assessed subclinical 
atherosclerosis and with an increased prevalence of clinically manifest CVD. In case-control studies, 
NAFLD has been linked with increased carotid artery intima-media thickness,[24, 25, 26, 27, 28] 
increased arterial wall stiffness,[29, 30] and impaired endothelium-dependent flow-mediated 
vasodilatation.[31, 32] Similarly, a meta-analysis of seven cross-sectional studies totalling 3497 
individuals concluded that ultrasound-diagnosed NAFLD was strongly associated with greater carotid-
artery intimal medial thickness and an increased prevalence of carotid atherosclerotic plaques.[33] 
These findings have since been supported by a larger meta-analysis that incorporated 27 studies and 
confirmed the association of NAFLD with various markers of subclinical atherosclerosis (including also 
increased coronary-artery calcium score) independent of traditional CVD risk factors and metabolic 
syndrome features.[34] Individuals with NAFLD amongst an occupational cohort of over 10000 South 
Korean people had an increased coronary-artery calcium score, independent of multiple CVD risk 
factors, including insulin resistance.[35] Case-control studies have also reported strong associations 
of NAFLD with early changes in left ventricular morphology and/or diastolic dysfunction,[36, 37, 38, 
39] impaired myocardial energy metabolism,[40, 41] and reduced coronary artery flow.[42]. Cohort 
studies in patients with biopsy-confirmed NAFLD/NASH also clearly demonstrated that CVD is the 
most common cause of death.[4, 5] 
 
Population-based cohort studies, such as the National Health and Nutrition Examination Survey 
(NHANES-III), also provide evidence of increased CVD prevalence in NAFLD. In approximately 11500 
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 6
adult NHANES participants, NAFLD (diagnosed by ultrasonography) remained significantly associated 
with an increased prevalence of CVD after adjusting for major demographic, clinical and metabolic 
confounders.[43, 44] An Italian study in nearly 3000 outpatients with T2DM also demonstrated that 
those with ultrasound-diagnosed NAFLD had a higher prevalence of coronary, cerebrovascular and 
peripheral vascular disease, independent of traditional CVD risk factors, diabetes-related variables 
and other potential confounders.[45] Amongst patients undergoing clinically indicated coronary 
angiography, the presence of NAFLD also independently correlated with the severity of coronary 
artery disease.[46, 47, 48] Recently, a systematic review and meta-analysis incorporating almost 
165000 participants in 34 studies (21 cross-sectional, 13 cohort studies) has provided further support 
for the association of NAFLD (diagnosed by biochemistry, imaging or histology) with atherosclerosis, 
hypertension and both prevalent and incident CVD.[49] 
 
Based on the available data, there seems little doubt that NAFLD is associated with increased CVD 
prevalence, an association that has been consistently replicated across different patient populations. 
Whether NAFLD is an independent CVD risk factor or simply a bystander that shares common 
aetiological factors remains controversial.[3] However, there is a growing body of evidence 
demonstrating that CVD is a clinical concern in NAFLD, and that patients with NAFLD are more likely to 
experience a CVD-related death than a liver-related death.[4, 5] Although some studies suggested that 
only patients with NASH rather than those with simple steatosis have an increased CVD mortality 
compared with the matched control population,[50, 51] a subsequent meta-analysis brought this into 
question. In that meta-analysis patients with NAFLD (as detected by histology or ultrasonography) had 
a substantially greater risk of CVD mortality than the matched control population but presence of 
NASH did not further increase risk of CVD mortality.[52] Further prospective studies in patients with 
biopsy-characterised NAFLD are needed to address this point, although some studies with a sufficiently 
long follow-up recently showed that fibrosis stage rather than NASH best predicts long-term survival 
outcomes of NAFLD patients.[4, 5] 
 
Several studies support an association between NAFLD and incident CVD. Recent retrospective 
cohort studies reported a significant association between ultrasound-diagnosed NAFLD and the 
progression of subclinical coronary or carotid atherosclerosis independent of multiple CVD risk 
factors. The risk of subclinical carotid/coronary atherosclerosis progression was also higher among 
NAFLD patients with increased non-invasive markers of advanced fibrosis at baseline (NAFLD fibrosis 
score, fibrosis-4 score or elevated gamma-glutamyltransferase levels).[53, 54] Additionally, the 
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 7
regression of NAFLD on ultrasound over time was associated with a decreased risk of subclinical 
carotid atherosclerosis development.[53]  
 
The presence of NAFLD at baseline, although defined clinically using the calculated fatty liver index 
(FLI), conferred an odds-ratio of 1.63 for subsequent development of carotid atherosclerotic plaques in 
a cohort of 1872 European patients.[55] Recent data also supports a bidirectional association between 
incident NAFLD and CVD risk factors. After controlling for potential confounding factors, including 
alcohol consumption, in 1051 participants of the Framingham Heart Study, individuals with NAFLD at 
baseline were more likely to subsequently develop incident hypertension and T2DM than those 
without NAFLD; conversely, those with metabolic risk factors (hypertriglyceridaemia, hypertension or 
T2DM) at baseline were more likely to develop incident NAFLD.[56] These findings are also consistent 
with natural history studies of NAFLD patients with serial liver biopsies where those with occurrence of 
incident T2DM or hypertension between biopsies were most likely to exhibit progressive liver 
fibrosis.[1, 2] A large number of observational studies also suggest that NAFLD is predictive of incident 
CVD events and death.[4, 50, 51, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67] Table 1 lists the principal 
retrospective and prospective studies that have addressed the relationship between NAFLD (defined 
radiologically or histologically) and risk of CVD events. Many of these studies were also included in an 
updated meta-analysis that incorporated a total of 16 unique, observational studies with 34043 adults 
and captured nearly 2600 CVD outcomes over a median of 6.9-year follow-up.[68] This meta-analysis 
concluded that that the presence of NAFLD (diagnosed by imaging or histology) conferred an odds-
ratio of 1.64 for fatal and non-fatal incident CVD events, a risk that appeared to increase further with 
greater severity of NAFLD and remained significant when only those studies where analysis was fully 
adjusted for potentially confounding covariates.[68] However, some of these studies have suggested 
that the increase in CVD risk may be limited to subgroups of NAFLD patients, such as those with 
advanced fibrosis,[57] T2DM [58] or men with an elevated gamma-glutamyltransferase level.[58] It is, 
therefore, conceivable that additional factors may modify the association between NAFLD and risk of 
CVD events. One such modifying factor may be genetic variation. 
 
Advances in our understanding of how genetic modifiers influence disease progression through 
genome-wide association studies are also relevant and have provided important insights into the 
cross-talk between NAFLD and CVD and how they may become dissociated.[69] Although the widely 
validated single nucleotide polymorphism, rs738409 (c.444 C>G, p.I148M) in patatin-like 
phospholipase domain-containing 3 (PNPLA3) confers an increased risk of NASH, hepatic fibrosis and 
Page 51 of 85
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 8
hepatocellular carcinoma, it has no apparent effect on CVD risk.[70, 71, 72] However, further well-
designed prospective studies are needed to better clarify this controversial issue.[70, 71, 72, 73] 
Recently, another non-synonymous genetic variant within a gene of unknown function called trans-
membrane 6 superfamily member 2, TM6SF2 (rs58542926 c.449 C>T, p.E167K), has been linked with 
NAFLD.[74] As with PNPLA3, carriage of the TM6SF2 minor (T) allele is associated with greater 
hepatic steatosis, more severe NASH and greater hepatic fibrosis/cirrhosis,[75, 76] but intriguingly, 
carriage of the more common major (C) allele promotes very-low density lipoprotein excretion, 
conferring an increased risk of dyslipidaemia and CVD.[76, 77] Thus, whilst in general NAFLD is 
associated with an increased risk of CVD, carriage of specific genetic modifiers might mean that these 
may become dissociated. In what has been described as the ‘catch-22 paradigm’, individuals that 
possess the TM6SF2 minor (T) allele will be more prone to liver-related morbidity, whilst those that 
carry the more common (C) allele may be at greater risk of CVD.[78] Whether the strength of this 
effect is sufficient to overcome the effects of many other environmental or genetic variants that 
influence outcome(s) and so be clinically relevant at an individual level does however remain to be 
definitely determined.[78] The relatively new field of epigenetics research is also providing exciting 
insights into the role of DNA methylation in the pathogenesis of NAFLD and how gene-environment 
interactions may influence CVD. [79, 80, 81, 82] 
 
Accumulating evidence also suggests that NAFLD is linked with valvular heart diseases (i.e., aortic-
valve sclerosis or mitral annulus calcification) and increased risk of cardiac arrhythmias (mainly atrial 
fibrillation and ventricular tachyarrhythmias) that may partly contribute to explain the increased risk 
of CVD events observed in patients with NAFLD.[83, 84, 85, 86, 87]  
 
Overall, therefore, the available evidence not only demonstrates the strong association between 
NAFLD and CVD but also supports the view that NAFLD increases CVD risk: a relationship that may be 
modified by a range of factors including genetic variation. This has important clinical implications 
that may influence the decision to institute primary prevention strategies with lipid-lowering, anti-
hypertensive or anti-platelet agents. At present, algorithms such as the Framingham risk equation or 
the SCORE risk charts for CVD risk assessment are used to guide initiation of preventative 
interventions. However, they are based on traditional CVD risk factors and do not include presence of 
NAFLD. Although the Framingham risk equation has been validated for use in patients with 
NAFLD,[88] it remains unclear whether the addition of NAFLD as a predictive factor in this or other 
CVD risk score systems can improve their ability to accurately predict future CVD events. Moreover, 
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 9
randomized clinical trials with CVD outcomes that focus on treatments for liver disease in NAFLD are 
also required in order to definitely establish a causal relationship between NAFLD and risk of CVD 
events. 
 
4. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF CHRONIC KIDNEY DISEASE  
Over the past decade, several population-based and hospital-based studies have shown that the 
prevalence of CKD (defined as estimated glomerular filtration rate [eGFR]<60 ml/min/1.73 m2, 
abnormal albuminuria or overt proteinuria) was markedly increased in patients with NAFLD as 
diagnosed by imaging [89, 90, 91, 92, 93, 94, 95, 96, 97, 98] or histology.[99, 100, 101, 102, 103] In 
these studies, the prevalence of CKD ranged from approximately 20% to 55% among patients with 
NAFLD compared to 5%-30% among those without NAFLD.[89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 
100, 101, 102, 103] Notably, in most of these studies the significant association between NAFLD and 
CKD persisted after adjustment for hypertension, T2DM and other known risk factors for CKD. Pan et al. 
recently reported that after adjustment for visceral fat accumulation and other cardiometabolic risk 
factors, there was a positive, graded relationship between intrahepatic triglyceride content, as 
measured by magnetic resonance spectroscopy, and the presence of CKD or abnormal albuminuria in 
obese individuals.[97] In a population-based study of 8270 Chinese adults with normal kidney function, 
NAFLD was independently associated also with low levels of albuminuria, defined as urine 
albumin/creatinine ratio below 30 mg/g.[104] The finding of a strong association between NAFLD and 
early kidney dysfunction (i.e., microalbuminuria or eGFR<90 ml/min/1.73 m
2
) has been also 
documented in a cohort of nearly 600 overweight or obese children.[98] Recognition of this kidney 
dysfunction in childhood is clinically important because the treatment to reverse it is more likely to be 
effective if applied early in the disease process. Interestingly, some case-control studies that used liver 
biopsy to diagnose NAFLD also reported a significant, graded relationship between the severity of 
NAFLD histology and the presence of either decreased eGFR or abnormal albuminuria.[99, 100, 101, 
102, 103] For example, in a case-control study, we found that patients with biopsy-confirmed NASH 
had a greater prevalence of abnormal albuminuria and CKD than matched control subjects without 
hepatic steatosis, and that the histological severity of NASH was independently associated with 
decreasing mean eGFR values (Fig. 2).[99] That said, it is important to underline that none of the 
above-mentioned studies have used renal biopsy to examine the pathology of the CKD; so, it remains 
currently unknown if NAFLD is associated with a specific type of kidney disease (though it is very likely 
that NAFLD contributes to kidney damage mainly through accelerated atherogenesis).[89, 90, 91, 92, 
93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103]  
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 10
Although the cross-sectional associations between NAFLD and CKD stages are strong and consistent 
across a wide range of patient populations, the data on whether NAFLD per se is causally linked to the 
development and progression of CKD remains debatable.[105, 106]  
 
In an occupational cohort of nearly 8500 non-diabetic and non-hypertensive South Korean men with 
preserved kidney function and no overt proteinuria at baseline who were followed-up for a mean 
period of 3.2 years, NAFLD (diagnosed by ultrasonography) was associated with an increased incidence 
of CKD (hazard ratio [HR] 1.60; 95% confidence interval [CI] 1.3-2.0).[107] This association remained 
significant after adjusting for body mass index, blood pressure, insulin resistance, plasma C-reactive 
protein and other potential confounding factors.[107] Similarly, in the Valpolicella Heart Diabetes 
Study, involving 1760 type 2 diabetic patients with preserved kidney function who were followed-up 
over a 6.5-year period, the presence of NAFLD on ultrasonography was associated with an increased 
incidence of CKD (HR 1.69; 95% CI 1.3-2.6) independently of traditional cardio-renal risk factors, 
diabetes-related variables and medication use.[108] Consistent with these findings, in a longitudinal 
cohort study of 261 type 1 diabetic adults with preserved kidney function at baseline, who were 
followed-up for a mean period of 5.2 years, NAFLD (diagnosed by ultrasonography) was associated 
with an approximately threefold increased incidence of CKD. Fig. 3 shows a Kaplan-Meier analysis of 
incidence curves for CKD over the follow-up period in patients with and without NAFLD at 
baseline.[109] Notably, measurement of NAFLD improved risk prediction for CKD in this patient cohort, 
independently of traditional cardio-renal risk factors (age, sex, duration of diabetes, haemoglobin A1c, 
hypertension, baseline eGFR and microalbuminuria [i.e., the last two factors being the strongest 
known risk factors for CKD]).[109]  
 
A 2014 systematic review and meta-analysis of 33 observational studies (including 20 cross-sectional 
and 13 prospective studies and involving nearly 64000 individuals) examined the relationship between 
NAFLD and risk of CKD.[110] NAFLD was diagnosed by biochemistry, imaging or histology, and CKD as 
either eGFR <60 ml/min/1.73 m2 or proteinuria. The results of this meta-analysis showed that NAFLD 
was associated with a nearly twofold increase in the prevalence and incidence of CKD. Similarly, 
although only a few studies used liver biopsy to diagnose NAFLD, the presence of histologically 
confirmed NASH was associated with an approximately 2.5-fold increased prevalence and incidence of 
CKD than simple steatosis. Moreover, the presence of advanced hepatic fibrosis was associated with a 
remarkably greater prevalence and incidence of CKD than non-advanced fibrosis. In all of these 
analyses, the significant association between NAFLD and CKD persisted after adjustment for pre-
existing diabetes, hypertension and other cardio-renal risk factors.[110]  
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 11
 
In line with these observations, in a cohort of 261 patients with biopsy-proven NASH, who were 
treated with lifestyle modifications for 52 weeks, Vilar-Gomez et al. found that improvement in 
histological NASH-related endpoints, achieved by weight loss, was independently associated with 
improvement in kidney function parameters.[111] 
 
Collectively, these findings provide robust evidence of a strong association between the presence and 
severity of NAFLD with the stage and risk of developing CKD. Therefore, these findings call for a more 
active and systematic search for CKD in patients with NAFLD. However, it is important to underline 
that the quality of some of the published studies is limited, and that causality remains to be definitely 
proven in larger clinical trials with incident CKD outcomes that focus on treatments for liver disease in 
NAFLD. Notably, all these studies used creatinine-based equations to estimate GFR (which do not 
perform well in patients with cirrhosis or severe obesity) instead of direct GFR measurements to define 
CKD. Furthermore, no detailed information was available in these studies about specific renal 
pathology/morphology associated with NAFLD. Further research is also needed to better elucidate the 
underlying mechanisms by which NAFLD contributes to the development and progression of CKD.  
 
 
5. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF TYPE 2 DIABETES  
Obesity and insulin resistance are key pathogenic factors for NAFLD and T2DM, and thus these two 
diseases commonly co-exist; NAFLD is present in up to 75% of patients with T2DM, whereas the 
prevalence of T2DM in adults with NAFLD is approximately 10-18%.[112, 113, 114] In the absence of 
T2DM, NAFLD is a marker of insulin resistance independent of obesity or visceral adiposity, and 
predicts a greater deterioration in insulin sensitivity with weight gain compared to matched non-
NAFLD individuals.[115] Concomitant with these mechanistic observations, there is now robust 
evidence from observational studies demonstrating an increased risk of incident T2DM following a 
diagnosis of NAFLD. It is also notable that, in dual biopsy studies, the development of incident T2DM 
was the strongest predictor of progression to NASH and liver fibrosis.[1]  
 
A significant association between mildly elevated serum liver enzymes and increased risk of incident 
T2DM was described nearly two decades ago.[116] A meta-analysis of 20 observational studies 
(involving a total of 117000 subjects belonging to different ethnic groups) found a 1.6-2.0 fold 
increased risk of incident T2DM when comparing the highest versus the lowest quartile of serum 
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 12
aminotransferase levels over a median follow-up of 5 years.[117] Nevertheless, serum 
aminotransferase levels are relatively insensitive markers of NAFLD. Predictive non-invasive scores, 
such as the fatty liver index or the NAFLD fatty liver score, incorporate serum liver enzymes with 
various metabolic variables, such as body mass index (BMI) and serum triglyceride levels, into their 
diagnostic algorithms, resulting in greater diagnostic accuracy for NAFLD than serum liver enzymes 
alone. Both of these non-invasive scores have been demonstrated to predict incident T2DM, 
however it is difficult to distinguish whether it is NAFLD itself or the metabolic variables within these 
scores, which are responsible for the increased T2DM risk.[118]  
 
More robust evidence of the existence of an association between NAFLD and incident T2DM arises 
from multiple large cohort studies with a median follow-up period of at least 5 years that used 
ultrasonography or, less commonly, computed tomography to diagnose NAFLD (Table 2). After 
adjusting for several potential confounding factors, NAFLD has been associated with a 1.5 to 2-fold 
increased risk of new-onset T2DM over a 5 to 10-year follow-up period.[119, 120, 121, 122, 123, 124, 
125, 126, 127, 128, 129] It is notable that the increased T2DM risk associated with NAFLD was 
observed in both sexes, however was typically higher in men, mirroring the male predominance in 
T2DM.[124, 128, 129] 
 
Notably, the risk of new-onset T2DM appears to diminish over time following the improvement or 
resolution of NAFLD, with some Asian cohort studies demonstrating T2DM incidence returning to 
that of subjects without fatty liver on ultrasonography.[129, 130, 131] This is likely to be closely 
related to temporal changes in body weight, although one study found NAFLD resolution to be 
associated with a lower incidence of T2DM independently of change in BMI.[130] Another study 
found NAFLD improvement was only associated with a reduced risk of incident T2DM in those who 
had a concomitant BMI reduction over time.[129] 
 
NAFLD appears to be additive to established metabolic risk factors of obesity and insulin resistance 
in increasing the risk of incident T2DM.[120, 127, 128, 132] One cohort study of 12853 South Korean 
non-diabetic individuals found that the risk of incident T2DM over 5 years increased 2.7 fold with a 
baseline diagnosis of fatty liver on ultrasound, and 3.7 fold with insulin resistance determined by 
homeostasis model of assessment, whereas their combination increased the risk to 6.7 fold.[132] 
Nevertheless, the interaction between insulin resistance, metabolic syndrome and NAFLD is complex 
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with several studies suggesting the association between NAFLD and incident T2DM to be modified 
by the severity of underlying insulin resistance or baseline body weight; two studies have also found 
that the risk of incident T2DM with NAFLD is limited to patients with either baseline impaired fasting 
glycaemia or those with high baseline levels of insulin resistance.[127, 133] Similarly, a Finnish study 
of hypertensive patients followed for 21 years found that NAFLD was associated with an increased 
risk of incident T2DM when co-existing with the metabolic syndrome, but not in its absence.[134] 
Surprisingly, however, two Japanese studies found the magnitude of risk of incident T2DM to be 
higher in patients who have NAFLD but are lean or have lower BMI values.[121, 128] This finding 
might be, at least in part, due to the lower sensitivity of ultrasonography for detecting NAFLD with 
increasing BMI, potentially leading to some misclassification bias. 
 
The severity of underlying NAFLD appears to influence the magnitude of future risk of T2DM, with 
increasing risk that parallels the severity of hepatic steatosis on ultrasonography or computed 
tomography.[122, 125, 126] Importantly, in these studies the T2DM risk associated with NAFLD 
remained significant even after adjustment for a range of common T2DM risk factors. Similarly, a 
Korean study found that only NAFLD patients with elevated alanine-aminotransferase levels had an 
increased risk of incident T2DM, which may reflect more severe hepatic steatosis or the 
histologically more aggressive subtype of NASH.[135] Correspondingly, patients with NASH have a 
higher risk of developing T2DM compared to those with simple steatosis, although it is not clear 
whether this risk is independent of confounding factors such as obesity.[50] Lastly, after 
stratification of NAFLD patients according to likelihood of advanced hepatic fibrosis by the NAFLD 
fibrosis score (NFS), those with high or intermediate NFS values are more than twice as likely to 
develop T2DM than those with low NFS values.[119] Although there is now convincing evidence that 
NAFLD is strongly associated with the risk of incident CKD in patients with type 1 or type 2 diabetes 
(as discussed previously), it remains unclear whether NAFLD or NASH are also independent risk 
factors for diabetic retinopathy (another microvascular complication of diabetes), with evidence 
limited only to cross-sectional studies with conflicting conclusions.[89, 136] 
 
It is important to underline that the majority of observational studies that examined the relationship 
between NAFLD and risk of incident T2DM are retrospective and originate from Asia where large 
populations undergo regular health check-ups including liver ultrasonography. Only one study from 
the United States found computed tomography-determined hepatic steatosis to be independently 
associated with increased risk of incident T2DM in a population that included Caucasians, Blacks and 
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Hispanics, however whether this risk differs according to race is unknown as a stratified analysis was 
not performed.[126] Additionally, as Asian and non-Asian populations have different adipose tissue 
distributions and cultural/genetic backgrounds, further evidence is needed in different ethnic and 
racial groups. Finally, the study by Ming et al. was the only one in which the diagnosis of diabetes 
was also based on 2-hour post-load plasma glucose levels.[123] 
 
Currently, it is unclear whether NAFLD is causally related to T2DM development or is simply a 
marker of other shared risk factors, such as visceral adipose tissue. Notably, some genetic conditions 
leading to intrahepatic triglyceride accumulation, such as familial hypobetalipoproteinemia, do not 
lead to increased insulin resistance, and genetic polymorphisms in the PNPLA3 gene (that also 
correlate with higher intrahepatic triglyceride content and increased risk of NASH, but are not 
systematically associated with insulin resistance and metabolic syndrome features) only appear to 
associate with T2DM in the presence of obesity, suggesting that other factors in addition to hepatic 
steatosis are important for the development of T2DM.[69, 137, 138]  
 
Despite the above caveats, a large number of cohort studies clearly demonstrated NAFLD to be 
associated with an approximate doubling of risk of incident T2DM. This association appears to be 
dose-dependent and is ameliorated with NAFLD improvement or resolution over time. Consequently, 
current clinical guidelines recommend routine screening of NAFLD patients for T2DM with fasting 
blood glucose or haemoglobin A1c levels or with a 75-g oral glucose tolerance test in high-risk 
groups.[139] 
 
6. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF COLORECTAL ADENOMAS/CANCER AND 
OTHER EXTRA-HEPATIC NEOPLASMS  
Patients with NAFLD typically have a range of metabolic risk factors associated with the 
development of neoplasia, including T2DM and obesity; consequently, extra-hepatic malignancy is 
the second commonest cause of death among patients with NAFLD.[4, 5] In addition, one 
community-based cohort study of T2DM patients suggested that NAFLD was associated with an 
increased risk of death from malignancy, suggesting an independent effect of NAFLD over and above 
co-existing metabolic risk factors.[140]   
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The strongest association between NAFLD and extra-hepatic neoplasia has been reported with 
colorectal adenomas (as summarized in Table 3). One Taiwanese study of 1522 individuals found a 
diagnosis of NAFLD in subjects with a normal baseline colonoscopy was associated with a 45% 
increased risk of future adenoma on subsequent colonoscopy 5 years later.[141] This association 
remained significant after adjustment for age, sex, smoking and metabolic risk factors. Two 
subsequent meta-analyses of 5 observational studies each, demonstrated a 1.5-1.7 fold increased 
risk of colorectal adenomas.[142, 143] NAFLD was also associated with multiple colorectal adenomas 
(≥3) and a tendency towards proximal lesions (right sided colonic adenomas). Whether the risk of 
colorectal adenoma increases with NASH compared to simple steatosis is unclear with two relatively 
small cross-sectional studies demonstrating conflicting results.[144, 145] Recently, a large cross-
sectional study of 26540 asymptomatic individuals from South Korea however, found the risk for any 
colorectal neoplasia and advanced colorectal neoplasia to be particularly increased in NAFLD 
patients with high NFS or other non-invasive fibrosis scores.[146] 
 
The risk of developing colorectal cancer also appears to be increased, with two large cohort studies 
of Korean and Chinese individuals undergoing colonoscopy (n=2315 and n=5517, respectively) 
finding a diagnosis of NAFLD on ultrasound to be significantly associated with an increased cancer 
risk of 1.87 (95% CI 1.4-2.6) and 3.08 (95% CI 1.02-9.3), respectively.[147, 148] Preliminary reports 
have also linked NAFLD with the occurrence of gastric and prostate cancers (reviewed in [149]), 
however further data is required before any definitive conclusions can be made. Further research is 
also needed to establish whether risk of these extra-hepatic cancers differs with severity of NAFLD. 
 
Nevertheless, the studies to date have been predominately cross-sectional, limiting any inference 
about causality and largely restricted to Asian populations. Currently, although a diagnosis of NAFLD 
is not sufficient to recommend screening colonoscopy, however evaluation of colonic symptoms and 
ensuring patients are enrolled in colorectal cancer screening programs as per recommendations for 
the general population is strongly recommended. Further evidence is needed to clarify the risk in 
patients aged 40-50 years of age who are not currently within routine screening guidelines. However, 
if the potential adverse impact of NAFLD on risk of colorectal adenomas/cancer will be confirmed in 
future large-scale prospective studies, there may be significant implications for screening and 
surveillance strategies given the growing number of NAFLD patients. 
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7. EPIDEMIOLOGICAL DATA LINKING NAFLD TO RISK OF OSTEOPOROSIS  
NAFLD is associated with multiple factors linked to decreased bone mineral density (BMD), including 
T2DM, obesity, insulin resistance, chronic inflammation, vitamin D3 deficiency and low levels of 
physical activity.[150] Consequently, several cross-sectional and case–control studies involving both 
adults and adolescents have found a significant association between low BMD or osteoporosis and 
NAFLD (reviewed in [150]). Worryingly, this association has been also reported in the paediatric age 
group, with one study of 38 obese children with biopsy-proven NAFLD reporting significantly lower 
BMD compared to 38 non-steatotic children matched for age, sex, ethnicity and BMI.[151] The 
degree of BMD fell with increasing severity of liver disease with patients with NASH having a lower 
level than those with simple steatosis.  
 
In adults, the association between NAFLD and osteoporosis is less consistent, with a meta-analysis of 
a total of 1276 individuals finding no significant differences in BMD between subjects with or 
without NAFLD, whereas a significant association with BMI was found.[152] Significant 
heterogeneity between studies however, limits conclusions from this meta-analysis. Subsequently, 
three large cohort studies totalling over 2500 individuals, all found a significant inverse association 
between BMD and NAFLD, although interestingly the association was limited to males and not seen 
in post-menopausal females.[153, 154, 155] The association between NAFLD and BMD was modest, 
however remained significant in these studies even after adjusting for several potential confounding 
factors, including age, weight, alcohol intake, smoking and metabolic risk factors. Increasing 
ultrasonographic severity of hepatic steatosis as well as serum alanine-aminotransferase levels 
correlated inversely with BMD.[153] A further cohort study of 7797 Chinese adults aged >40 years 
confirms the existence of a sex-specific association with a higher rate of recent osteoporotic 
fractures in males with NAFLD compared to those without (3.6% vs. 1.7%, p=0.003), with no 
difference seen in females.[156] Overall, males with NAFLD had a 2.5-fold increased risk of recent 
osteoporotic fractures even after adjustment for age, smoking, alcohol intake, physical activity, 
metabolic risk factors, kidney function and use of glucocorticoids or osteoporosis medications.[156] 
The male specific association suggests a sex-specific interaction between hepatic steatosis and bone 
metabolism, or that other factors in females, such as oestrogen status, may dominate the risk of 
osteoporosis.  
 
Collectively, these findings argue for awareness of BMD among patients with NAFLD. However, it is 
important to note that the available data is limited to cross-sectional studies largely from Asian 
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populations. The majority of studies focus on BMD rather than bone fracture rate and further 
evidence is required to clarify whether NAFLD patients (in particular males) should be screened for 
osteoporosis.  
 
8. PUTATIVE MECHANISMS LINKING NAFLD TO EXTRA-HEPATIC CONDITIONS  
Extra-hepatic pathologic conditions in NAFLD are closely linked to the presence of local (i.e., in the 
liver, adipose tissue, vessels and heart) and systemic inflammation. Chronic low-grade inflammation 
accompanies many metabolic disorders, such as T2DM or NAFLD.[157] It has been demonstrated 
that inflammatory pathways such as interleukin-1 type cytokines are driving forces of disease 
processes in NAFLD and correlate with prognosis of liver disease.[158, 159] Hepatic inflammation 
might not only be responsible for the overall degree of hepatic fibrosis and thereby prognosis of this 
disorder but might also control insulin resistance. Hepatic/peripheral insulin resistance (i.e., a 
hallmark in most patients with NAFLD) and metabolic inflammation are frequently observed in 
parallel, and research from the past has tried to connect these two phenomena.[160] The origin of 
chronic inflammatory processes observed in NAFLD is still a matter of discussion as multiple parallel 
‘hits’ might control and regulate disease process.[161] Besides lipotoxicity, the gastrointestinal tract 
with its significantly altered microbiota could reflect one of the early events in disease development. 
In addition, abdominal visceral adipose tissue accumulation is another ‘hot’ candidate reflecting a 
major site of chronic inflammation in NAFLD as adipose tissue inflammation is commonly observed 
in obesity, T2DM and NAFLD. Indeed, it has been shown that the inflamed (‘dysfunctional’) adipose 
tissue in obesity might generate almost 50% of circulating interleukin-6 thereby contributing 
substantially to systemic chronic inflammation.[162] The importance of visceral adipose tissue as 
site of chronic inflammation is further supported by some studies demonstrating that the lack of 
adipocyte 5' AMP-activated protein kinase worsens insulin resistance and liver disease by affecting 
brown and beige adipose tissue function.[163] Additionally, adipose tissue-specific insulin receptor 
knockout mice develop more severe NAFLD with histological evidence of ballooning degeneration 
further supporting the notion that the adipose tissue is of key importance in the development and 
progression of NAFLD.[164] In contrast, recent research has found that adipose tissue type I 
interferon signalling may protect from metabolic dysfunction.[165] 
 
8.1 Nutrition and dietary factors 
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Nutrition is critically involved in the pathogenesis of NAFLD besides from the fact that NAFLD is 
mainly a disease of the obese population. Over-nutrition and certain dietary factors have been 
demonstrated to induce chronic low-grade inflammation.[166, 167] Epidemiologic studies have 
shown that diet can affect inflammatory processes and the immune system directly, and also 
through interactions with the gut microbiota. Western diets are able to promote chronic 
inflammatory processes by many pathways. A high salt content may induce interleukin-17 producing 
T-helper cells and thereby inflammation.[168] Dietary fatty acids promote inflammation through 
several mechanisms, including direct effects on immune cells, activation of toll-like receptors and 
cytokine cascades [169] and affecting intestinal permeability.[170] Mice with a loss of junctional 
adhesion molecule A (JAM-A) have a defect intestinal epithelial barrier and exhibit more prominent 
NASH, and colonic tissue from patients with NAFLD have lower levels of JAM-A and higher levels of 
inflammation compared to healthy controls.[171] In healthy individuals, a high-fat Western diet 
induces endotoxinaema and, therefore, might contribute to the observed chronic inflammation in 
NAFLD.[172] A diet rich in saturated milk-derived fatty acids worsens colitis in interleukin-10 
deficient mice via profound changes of the gut microbiota and an increased T-helper 1 cell 
response.[173] Many studies have also associated dietary phosphatidylcholine and L-carnitine 
consumption with generation of specific metabolites (i.e., trimethylamine [TMA] and TMA N-oxide 
[TMAO]) and future CVD events.[174] Not surprisingly, dietary interventions might be able to 
reverse a Western-diet induced liver phenotype as shown e.g. for citrulline.[175] Overall, the 
composition of Western diets might not only contribute to the development/progression of NAFLD 
via generation of overweight and obesity, but also induce activation of specific inflammatory 
pathways. 
 
8.2 Gut microbiota 
Evidence is increasing that the gut microbiota might contribute to the pathogenesis of NAFLD. 
NAFLD reflects a prototypic disease of innate immunity and it is expected that certain bacteria in the 
intestinal tract activate various pathways of innate immunity in the case of disease.[176] In several 
mouse models, the microbiota affects hepatic steatosis and fat storage. Human studies from the 
past years have also supported a role for the microbiota in NAFLD. Actinobacteria were increased 
whereas Bacteroidetes were reduced dependent on liver disease activity as demonstrated in a 
paediatric study population.[177] At species levels, Oscillobacter decreased in NAFLD whereas 
Ruminococcus, Blautia, and Dorea increased especially in patients with NASH.[177] Another study 
assessed the gut microbiota and severity of histology-proven NAFLD in 57 patients.[178] Bacteroides 
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abundance increased depending on severity of disease, whereas Prevotella abundance decreased. 
Ruminococcus abundance increased in more severe disease, especially if advanced hepatic fibrosis 
was diagnosed.[178] Overall, many studies from the past years clearly highlighted a role for the gut 
microbiota in obesity-related disorders supporting the assumption that NASH might be associated 
with a “microbiome signature” which could contribute to initiation of inflammation. It has to be 
acknowledged, however, that these early studies are rather descriptive and neither studies (either 
preclinical or clinical) have so far identified certain bacterial strains, which act pro-inflammatory and 
are indeed involved in disease pathogenesis. The altered microbiome in patients with NAFLD could 
also be involve  in the development of NAFLD-associated malignancy both in the liver [179] and in 
the gastrointestinal tract.[180] 
 
8.3 Cytokines/adipocytokines 
It is well established that proinflammatory cytokines and transcription factors are highly expressed 
in various tissues, such as the adipose tissue or liver, in NAFLD and a large number of different 
immune cells and, especially, tissue macrophages may contribute to the inflammatory phenotype. 
Various proinflammatory cytokines, such as TNF-alpha or interleukin-6, are activated in different 
tissues but especially, in adipose tissue and in the liver of patients with NAFLD/NASH.[181] There is 
substantial evidence that activation of the transcription of nuclear factor–kappa B (NF-κB) and 
downstream inflammatory signalling pathways are involved in metabolic liver inflammation and 
associated hepatic insulin resistance.[182, 183] Receptor activator of NF-κB (RANKL), a prototypic 
activator of NF-κB, regulates hepatic insulin sensitivity.[184] Deletion of hepatic MyD88 results in 
liver inflammation and hepatic insulin resistance also affecting the gut microbiota composition and 
metabolome.[185] Therefore, several studies using hepatocyte-specific targeting of genes have now 
strongly supported the notion that hepatocytes are major metabolic “players” in the development of 
metabolic inflammation in and beyond the liver. 
 
Chronic inflammation and cytokine activation is a driving force in the evolution of malignancy and, 
therefore, it is expected that patients with NAFLD exhibit a high rate of liver and extra-hepatic 
malignancies.[144, 186] Chronic interleukin-6 over-expression has been found to result in the 
generation of liver tumours.[187] In these studies, the development of obesity-promoted 
hepatocellular carcinoma was dependent on enhanced production of the tumour-promoting 
cytokines interleukin-6 and TNF-alpha, which cause hepatic inflammation and activation of the 
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oncogenic transcription factor STAT3. Besides several cytokines also certain adipocytokines, such as 
adiponectin and leptin, might contribute to systemic inflammatory processes and associated 
pathologies in NAFLD.[188, 189] For example, NAFLD is associated with hypoadiponectinaemia and 
lower adiponectin levels correlate with colorectal cancer/adenoma incidence.[190, 191] Low-level 
plasma adiponectin is especially associated with KRAS-mutant colorectal cancer risk.[192] Therefore, 
it may be concluded that chronic activation of cytokine/adipocytokine cascades as observed in 
NAFLD might contribute substantially to the extra-hepatic chronic diseases observed in NAFLD 
ranging from CVD to osteoporosis and especially also hepatic and extra-hepatic cancers.  
 
9. CONCLUSIONS  
This review further reinforces the view that NAFLD is a multisystem disease that affects many extra-
hepatic organ systems and interacts with the regulation of multiple metabolic pathways. NAFLD is 
associated not only with liver-related morbidity and mortality, but also with an increased risk of 
developing important extra-hepatic chronic diseases, such as CVD, T2DM and CKD. Emerging data 
also suggests NAFLD may be a risk factor for colonic adenomas/cancer and decreased bone mineral 
density, particularly among men. Clear evidence indicates that CVD is the leading cause of death in 
patients with NAFLD. This implies that patients with NAFLD should undergo careful cardiovascular 
surveillance. In line with this implication, given that CVD complications dictate the outcome(s) in 
patients with NAFLD more frequently and to a greater extent than does the progression of liver 
disease, the recent European clinical practice guidelines have recommended CVD risk assessment in 
all patients with NAFLD.[139]  
 
There is a growing body of epidemiological and experimental evidence suggesting that NAFLD, 
especially its necro-inflammatory form, exacerbates hepatic/peripheral insulin resistance, 
predisposes to atherogenic dyslipidaemia and releases a variety of proinflammatory, procoagulant, 
thrombogenic and profibrogenic factors that may promote the development of CVD, CKD, T2DM and 
other extra-hepatic chronic diseases. 
 
However, although all these mechanisms plausibly link NAFLD to the development and progression 
of CVD, CKD and other extra-hepatic diseases, no studies to date have proven a cause-and-effect 
relationship and further research is certainly needed to gain mechanistic insights into the 
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pathophysiology linking NAFLD to the development and progression of these extra-hepatic chronic 
diseases. 
 
In the meantime, we believe that the clinical implication of these findings is that a diagnosis of 
NAFLD may identify a subset of the general population, which is exposed to an increased risk of 
developing some important extra-hepatic chronic diseases. Therefore, patients with NAFLD might 
benefit from more intensive surveillance or early treatment interventions to decrease the risk of 
developing CVD, CKD, T2DM and other extra-hepatic manifestations. Thus, clinicians who manage 
patients with NAFLD, especially those with NASH with varying amounts of fibrosis, not only should 
focus on liver disease, but also should recognize the increased risk of CVD, CKD, T2DM and other 
serious extra-hepatic manifestations of these patients, screen them for conventional risk factors and 
undertake early, aggressive risk factor modification(s). 
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FIGURE LEGENDS 
 
Figure 1. Nonalcoholic fatty liver disease: a multisystem disease.  
Reported associations between NAFLD and various human diseases. 
 
Figure 2. Kidney function in patients with non-alcoholic steatohepatitis. 
Panel A shows the prevalence of both abnormal albuminuria (i.e., urinary albumin-to-creatinine 
ratio≥30 mg/g) and chronic kidney disease (CKD; defined as eGFRMDRD <60 ml/min/1.73 m
2 or abnormal 
albuminuria) in 80 overweight patients with biopsy-proven NASH and 80 non-steatotic control 
individuals who were matched for age, sex and body mass index. Panel B shows the adjusted means 
(±standard deviations) of estimated glomerular filtration rate in patients with NASH according to the 
histologic stage of hepatic fibrosis (from 0, indicating no fibrosis, to 3, indicating advanced fibrosis; 
patients with cirrhosis [i.e., those with stage 4 fibrosis] were not included in the study). Data have 
been adjusted for age, sex, body mass index, waist circumference, hypertension status, plasma 
triglyceride concentrations, and insulin resistance (as estimated on the basis of a homeostasis model 
assessment). Data are from Targher et al.[99] Reproduced with permission. 
 
Figure 3. Risk of incident chronic kidney disease in patients with type 1 diabetes and non-alcoholic 
fatty liver disease. 
Incidence curves for CKD (defined as occurrence of estimated glomerular filtration rate [eGFR]<60 
ml/min/1.73 m
2
 or macroalbuminuria) in a cohort of 261 type 1 diabetic adults with (dotted line) and 
without (solid line) NAFLD on ultrasonography over a mean follow-up period of 5.2 years. All patients 
had preserved kidney function (eGFRMDRD≥60 ml/min/1.73 m
2) and no macroalbuminuria at baseline. 
Patients with known liver diseases and those with a prior history of cardiovascular disease were 
excluded from the study. Data are from Targher et al.[109] Reproduced with permission. 
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TABLE 1. Selected observational studies exploring the risk of CVD in patients with NAFLD as diagnosed by histology or imaging (studies were ordered by 
methodology of NAFLD diagnosis and publication year). 
Authors,  
Year [ref.] 
Study  
Population 
Follow-up 
Length  
NAFLD  
Diagnosis 
Study  
Outcomes 
Main  
Findings  
Matteoni CA et al., 
1999 [61] 
Retrospective cohort of 132 US patients with 
NAFLD and raised serum liver enzymes 
18 years Histology All-cause and cause 
specific mortality 
Patients with NASH had higher rates of all-cause and 
liver-related mortality than those without. CVD death 
rate did not differ between the groups 
Dam-Larsen S et al., 
2004 [62]  
Retrospective cohort of 109 Danish patients 
with nonalcoholic simple steatosis (without 
NASH at baseline) 
16.7 years Histology All-cause and cause specific 
mortality 
No significant difference in death rates between 
patients with simple steatosis and the general 
population 
Adams LA et al. 2005 
[64]  
Retrospective community-based cohort of 420 
US patients with NAFLD  
7.6 years Histology & 
Imaging 
All-cause and cause specific 
mortality 
Patients with NAFLD (especially those with cirrhosis 
and NASH) had higher rates of all-cause, CVD and 
liver-related mortality than the matched general 
population 
Ekstedt M et al. 2006 
[50] 
Retrospective cohort of 129 Sweden patients 
with NAFLD and raised serum liver enzymes 
13.7 years Histology All-cause and cause 
specific mortality 
Patients with NASH, but not those with simple 
steatosis, had higher rates of all-cause (~2 fold), CVD 
(~2 fold) and liver-related (~10 fold) mortality than 
the reference population 
Rafiq N et al. 2009 [63] Retrospective cohort of 173 US patients with 
NAFLD and raised serum liver enzymes 
13 years Histology All-cause and cause 
specific mortality 
CVD, malignancy and liver-related complications were 
the most common causes of mortality 
Söderberg C et al. 2010 
[51]  
Retrospective cohort of 118 Sweden patients 
with NAFLD and raised serum liver enzymes 
24 years Histology All-cause and cause specific 
mortality 
Patients with NASH, but not those with simple 
steatosis, had higher rates of all-cause (~2 fold), CVD 
(~2 fold) and liver-related mortality than the matched 
general population 
Ekstedt et al. 2015 [4] Retrospective cohort of 229 Sweden patients 
with biopsy proven NAFLD 
26.4 ± 5.6 
years 
Histology All cause and disease-
specific mortality 
NAFLD patients have increased overall mortality (HR 
1.29, 95% CI 1.04-1.59), with a high risk of death from 
CVD (HR 1.55, 95% CI 1.11-2.15) and liver-related 
disease. Stage of fibrosis rather than presence of NASH 
predicted both overall and disease-specific mortality 
Fracanzani et al. 2016 
[193] 
Prospective case-control study of 125 Italian 
patients with NAFLD and 250 age- and sex-
matched control individuals without known liver 
diseases 
10 years Histology & 
Ultrasound 
Non-fatal CVD events 
(acute coronary syndrome, 
coronary revascularization 
procedures, ischemic stroke 
or transitory ischemic 
attacks as combined 
endpoint) 
NAFLD was independently associated with incident 
nonfatal CHD events  (HR 1.99, 95% CI 1.01-3.91) 
Jepsen P et al. 2003 
[65] 
Retrospective cohort of 1,800 Danish patients 
discharged with a hospital diagnosis of NAFLD  
6.2 years Ultrasound & 
Liver enzymes 
All-cause and cause 
specific mortality 
Patients with NAFLD had higher rates of all-cause (2.6 
fold), CVD (2.1 fold) and liver-related (19.7 fold) 
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mortality than the general population 
Hamaguchi M et 
al.[59]   
Community-based cohort of 1,637 Japanese 
apparently healthy individuals  
5 years Ultrasound Non-fatal coronary heart 
disease and stroke 
NAFLD was independently associated with increased 
risk of nonfatal CVD events (HR 4.10, 95% CI 1.6-10.7) 
Targher G et al. 2007 
[45]   
Prospective cohort of 2,103 Italian type 2 
diabetic individuals without baseline viral 
hepatitis and CVD 
6.5 years Ultrasound CVD mortality and non-
fatal   myocardial 
infarction, ischemic stroke 
and revascularization 
procedures (combined 
endpoint) 
NAFLD was independently associated with increased 
risk of fatal and non-fatal CVD events (HR 1.87, 95% CI 
1.2-2.6) 
Haring R et al. 2007 
[58]   
Population-based cohort study of 4,160 German 
adult men and women without baseline viral 
hepatitis or cirrhosis 
7.3 years Ultrasound All-cause and cause 
specific mortality 
NAFLD was independently associated with increased 
risk of all-cause and CVD mortality in men (HR 6.2, 
95% CI 1.2-31.6) 
Zhou J et al. 2012 [67]   Community-based cohort study of 3,543 
Chinese adult men and women  
4 years Ultrasound All-cause and cause 
specific mortality 
Patients with NAFLD had ~3-fold higher rates of all-
cause and CVD mortality than those without NAFLD 
Stepanova M et al. 
2013 [43] & Lazo M et 
al. 2011 [44] 
National-based cohort study of 11,371 US adult 
participants from the Third National Health and 
Nutrition Examination Survey 1988-94  
14.5 years Ultrasound  All-cause and cause 
specific mortality 
No significant association between NAFLD and all-
cause and cause specific mortality 
Pisto et al. 2014 [60] Population-based, randomly recruited cohort of 
988 middle-aged Finnish participants 
~18 years Ultrasound Fatal and non-fatal CVD 
events  
Severe NAFLD did not significantly predict the risk of 
CVD events after adjustment for potential 
confounders, including insulin resistance 
Wong VW et al. 2016 
[48] 
612 consecutive Chinese patients undergoing 
coronary angiograms without known liver 
diseases 
6 years Ultrasound  Fatal and non-fatal CVD 
events, heart failure or 
secondary coronary 
interventions (combined 
endpoint) 
NAFLD patients, compared with those without, were 
more likely to have >50% stenosis in one or more 
coronary arteries and therefore require percutaneous 
coronary intervention. NAFLD was not significantly 
associated with fatal and non-fatal CVD events 
Mantovani et al. 2016 
[194] 
Retrospective cohort of 286 Italian type 1 
diabetic adults without known liver diseases 
5.3 ± 2 years Ultrasound Non-fatal ischemic heart 
disease, nonfatal ischemic 
stroke or 
coronary/peripheral artery 
revascularization 
procedures (combined 
endpoint) 
NAFLD was independently associated with an 
increased risk of non-fatal CVD events (HR 6.73, 95% CI 
1.2-38) 
Treeprasertsuk S et al. 
2012 [195] 
Community-based cohort of 309 US patients 
with NAFLD  
11.5±4.1 
years 
Ultrasound & 
Computed 
tomography 
New-onset CVD NAFLD patients have a higher 10-year CHD risk than 
the general population of the same age and sex 
Kim et al. 2013 [57] National-based cohort study of 11,154 US adult 
participants from the Third National Health and 
Nutrition Examination Survey 1988-94 
14.5 years Ultrasound & 
Non-invasive 
fibrosis markers 
(NFS/APRI/FIB4) 
All-cause and cause specific 
mortality 
NAFLD not associated with increased mortality. 
However, advanced fibrosis, as determined by non-
invasive fibrosis markers, is a significant predictor of 
mortality, mainly from CVD causes, independent of 
other known factors 
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Zeb et al. 2016 [196] Prospective cohort study of 4119 US adult 
participants who were free of CVD and known 
liver diseases at baseline (The Multi-Ethnic Study 
of Atherosclerosis) 
7.6 years 
(median) 
Computed 
tomography 
All-cause mortality and CVD 
events (myocardial 
infarction, resuscitated 
cardiac arrest, angina or 
coronary revascularization 
procedures) 
NAFLD was independently associated with incident 
CHD events (HR 1.42, 95% CI 1.00-2.03) 
Abbreviations: CHD=coronary heart disease, CVD=cardiovascular disease; HR=hazard ratio; CI=confidence intervals; T2DM=type 2 diabetes mellitus.  
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TABLE 2. Retrospective or prospective cohort studies examining NAFLD (as detected either by ultrasonography or by computed tomography) as a risk 
factor for incident type 2 diabetes mellitus. 
Authors, 
Year [ref.] 
Country Sample 
Size 
Follow-up 
(median, 
years) 
T2DM Diagnosis T2DM% at Follow-up Adjusted Odds Ratio(s)  
(±95% CI) 
Adjusted Variables 
Okamoto et 
al.  
2003[124] 
Japan 840 10.0 FBG ≥140 mg/dl (≥7.8 mmol/l) or 
HbA1c ≥6.5% or T2DM 
medications 
14.1% (males) 4.3% 
(females) 
1.8  
(0.9-3.5) 
Age, sex, BMI, weight gain, FBG, HbA1c, alcohol intake, 
family history of diabetes 
Kim et al.  
2008[122] 
South Korea 5372 5.0  FBG ≥126 mg/dl (≥7.0 mmol/l) or 
T2DM medications or past history 
4.3% 1.5  
(1.1-2.2) 
Age, sex, BMI, smoking, family history of diabetes, ALT, 
FBG, triglycerides, HDL-cholesterol 
Yamada et 
al. 
2010[128] 
Japan 12375 5.0 FBG ≥126 mg/dl or T2DM 
medications 
1% (males) 1.9 (1.9-2.8) males Age, BMI, blood pressure, alcohol intake, smoking 
 0.5% (females) 2.1 (2.5-4.7) females 
Sung et al.  
2011[127] 
South Korea 11091 5.0 Not reported 1.6% 2.05  
(1.35-3.12) 
Age, sex, BMI, alcohol, education, smoking, exercise 
Chang et al.   
2013[119] 
South Korea 38291 5.1 FBG ≥126 mg/dl or HbA1c ≥6.5% 
or T2DM medications 
1.1% annual 
incidence 
2.0 (1.8-2.2) for low NFS 
4.7 (3.7-6.1) for 
intermediate/high NFS 
Sex, smoking, alcohol intake, exercise, family history of 
diabetes, total cholesterol, triglycerides, HDL-
cholesterol, CRP, HOMA-insulin resistance 
Park et al.  
2013 [125] 
South Korea 25232 
(men) 
5.0 FBG ≥126 mg/dl or HbA1c ≥6.5% 
or T2DM medications or past 
history 
8.4% 1.73 (1.00-3.01) Age, waist circumference, triglycerides, HDL-cholesterol, 
CRP, HOMA-insulin resistance, creatinine, blood 
pressure, family history of diabetes, exercise, MetS 
Shah et al.  
2015 [126] 
USA 3153 9.1 FBG ≥126 mg/dl or T2DM 
medications or past history 
6.9% 2.06 (1.52-2.79)* Age, sex, race, BMI, waist circumference, family history 
of diabetes, blood pressure, FBG, HDL-cholesterol, 
triglycerides, exercise, CRP, statin use 
Yamakazi et 
al. 
2015[129] 
Japan 4604 11.3 FBG ≥126 mg/dl or HbA1c ≥6.5% 
or T2DM medications or past 
history 
6.1% 2.37 (1.60-3.52) Age, sex, BMI, impaired fasting glycaemia, family history, 
dyslipidaemia, blood pressure, exercise 
Ming et al.  
2015[123] 
China 508 5.0 FBG ≥126 mg/dl or 2-h OGTT 
≥200 mg/dl or T2DM medications  
3.9% 4.46 (1.86-10.73) Age, sex, BMI, education, smoking, alcohol intake, 
exercise, family history, blood pressure, FBG, HDL-
cholesterol, triglycerides 
Chen et al.  
2016[120] 
China 6542 6.0 FBG ≥126 mg/dl or T2DM 
medications or past history 
5.6% 2.17 (1.53-3.01)* Age, BMI, triglycerides, impaired fasting glycaemia status 
Fukada et al.  
2016[121] 
Japan 4629 12.8 FBG ≥126 mg/dl or HbA1c ≥6.5% 
or T2DM medications 
7.6% 3.6 (2.1-5.8) for lean 
6.8 (5.2-8.9) for obese 
Age, sex, smoking, alcohol intake, exercise, HbA1c, 
family history of diabetes 
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Footnote: Only cohort studies with a median follow-up period of at least 5 years are presented. The study by Shah et al. is the only one in which the diagnosis of NAFLD was based on 
computed tomography. The study by Ming et al. is the only one in which the diagnosis of diabetes mellitus was also based on 2-hour OGTT glucose levels *Hazard ratio presented.   
Abbreviations: T2DM=type 2 diabetes mellitus; BMI=body mass index; FBG=fasting blood glucose; HbA1c=haemoglobin A1c; ALT=alanine aminotransferase; OGTT=oral glucose tolerance test; 
HDL=high-density lipoprotein; HOMA=homeostasis model assessment; CRP=C-reactive protein; MetS=metabolic syndrome; NFS=NAFLD fibrosis score. 
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TABLE 3. Cohort studies examining NAFLD as a possible risk factor for colorectal neoplasia. 
Authors, 
Year [ref.] 
Country Study 
Design 
Sample 
Size 
Follow-up 
(median, 
years) 
Adenoma (%) Carcinoma (%) Adjusted Odds Ratio(s)  
(±95% CI) 
Adjusted Variables 
Non-NAFLD NAFLD Non-NAFLD NAFLD  Adenoma Carcinoma 
Hwang et al. 
2010[197] 
South 
Korea 
Cross-
sectional 
2917 NA 16% 24% - - 1.28 
(1.03-1.60) 
- Age, sex, smoking, T2DM, blood 
pressure, MetS 
Touzin et al.  
2011[145] 
USA Cross-
sectional 
233 NA 25% 24% - - - - - 
Wong et al. 
2011[144] 
Hong Kong Cross-
sectional 
380 NA 22% 35% 0.6% 1% 1.61 
(0.90-2.90) 
- Age, sex, BMI, smoking, family 
history, blood pressure, T2DM, 
aspirin use 
Stadlmayr 
et al. 
2011[198] 
Austria Cross-
sectional 
1211 NA 17% 28% 0.1% 0.9% 1.47  
(1.08-2.00) 
- Age, sex, BMI, glucose intolerance 
status 
Lin et al. 
2014 [148] 
China Cross-
sectional 
2315 NA 56% 44% 18% 29% 0.86  
(0.61-1.20) 
1.87 
(1.36-2.57) 
Age, sex, smoking, BMI, alcohol 
intake, T2DM, blood pressure, 
lipids, serum liver enzymes 
Bhatt et al. 
2015[199] 
USA Cross-
sectional 
591
$ 
NA 21% 32% 0% 0% 1.95 
(1.09-3.48) 
- Age, ethnicity, BMI, blood 
pressure, alcohol intake, smoking, 
MELD or Child-Pugh classes 
Basyigit et 
al. 
2015[200] 
Turkey Cross-
sectional 
127 NA 26% 20% 24% 5% 0.63 
(0.46-1.65) 
0.13 
(0.12-0.31) 
Age, sex, obesity, T2DM, MetS 
Ahn et al. 
2017[146] 
South 
Korea 
Cross-
sectional 
26540 NA 29% 38% - - 1.10  
(1.03-1.17) 
- Age, sex, BMI, smoking, alcohol 
intake, family history, aspirin use, 
MetS factors 
Lee et al. 
2012[147] 
South 
Korea 
Cohort 5517 
(women) 
7 years - - - - 1.94  
(1.11-3.40) 
3.08 
(1.02-9.34) 
Age, smoking, MetS  
Huang et al. 
2013[141] 
Taiwan Cohort 1522* 5 years 39% 56% - - 1.45  
(1.07-1.98) 
- Age, sex BMI, smoking, blood 
pressure, T2DM, MetS 
Footnote: *All had negative baseline colonoscopy. 
$
All patients being evaluated for liver transplantation.  
Abbreviations: T2DM=type 2 diabetes; BMI=body mass index; MetS=metabolic syndrome; NA=not applicable.
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